Patient ID,Diagnosis Age,Cancer Type,Cancer Type Detailed,Mutation Count,Oncotree Code,Overall Survival (Months),Overall Survival Status,Number of Samples Per Patient,Sample Type,Somatic Status,TMB (nonsynonymous),Primary Tumor Site,Sex,Analysis Cohort,Biopsy Cohort,Biopsy Site,HRD Score,Immune Checkpoint Inhibitor,ICI Treatment Best Response,ICI Durable Clinical Benefit,Mutation Category,Immune Checkpoint Inhibitor Treated,ICI Treatment Catgory,Tumor Content,T Cells CD4 Memory Activated Score,T Cells CD4 Memory Resting Score,T Cells CD4 Naive Score,T Cells CD8 Score,T Cells Follicular Helper Score,T Cells Gamma Delta Score,T Cells Regulatory Tregs Score
11004,30,Colorectal Cancer,Colon Adenocarcinoma,115,COAD,8.11,1:DECEASED,1,Metastatic,Matched,3.933333333,Colon,Female,COLO,Liver,Liver,16,NA,NA,NA,NA,No,NA,73,NA,NA,NA,NA,NA,NA,NA
11307,48,Breast Cancer,Breast Invasive Ductal Carcinoma,47,IDC,27.46,1:DECEASED,1,Metastatic,Matched,1.6,Breast,Female,BRCA,Liver,Liver,31,NA,NA,NA,NA,No,NA,59,NA,NA,NA,NA,NA,NA,NA
11698,64,"Skin Cancer, Non-Melanoma",Basal Cell Carcinoma,2786,BCC,83.9,1:DECEASED,1,Metastatic,Matched,94.8,Skin,Male,BCC,Skin,Skin,35,NA,NA,NA,NA,No,NA,43,NA,NA,NA,NA,NA,NA,NA
12255,34,Embryonal Tumor,Atypical Teratoid/Rhabdoid Tumor,32,ATRT,9.66,1:DECEASED,1,Local Recurrence,Matched,1.066666667,NA,Male,SARC,Head & Neck,Sinus,0,NA,NA,NA,NA,No,NA,60,NA,NA,NA,NA,NA,NA,NA
13009,NA,Mature B-Cell Neoplasms,Mantle Cell Lymphoma,35,MCL,72.14,0:LIVING,1,Local Recurrence,Matched,1.133333333,Blood,Female,LYMP,Bone,Bone Marrow,1,NA,NA,NA,NA,No,NA,100,NA,NA,NA,NA,NA,NA,NA
13261,44,Head and Neck Cancer,Nasopharyngeal Carcinoma,42,NPC,53.68,1:DECEASED,1,Metastatic,Matched,1.4,Sinus,Male,HNSC,Liver,Liver,49,NA,NA,NA,NA,No,NA,50,NA,NA,NA,NA,NA,NA,NA
13268,35,Breast Cancer,Breast Invasive Ductal Carcinoma,65,IDC,71.71,0:LIVING,1,Metastatic,Matched,2.166666667,Breast,Female,BRCA,Lymphatic System,Lymph Node,27,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
13269,64,Colorectal Cancer,Colon Adenocarcinoma,104,COAD,60.09,1:DECEASED,1,Metastatic,Matched,3.533333333,Colon,Female,COLO,Abdomen,Abdominal Wall,19,NA,NA,NA,NA,No,NA,47,NA,NA,NA,NA,NA,NA,NA
13577,51,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,211,LUAD,27.69,1:DECEASED,1,Metastatic,Matched,7.1,Lung,Male,LUNG,Liver,Liver,29,NA,NA,NA,NA,No,NA,57,NA,NA,NA,NA,NA,NA,NA
13764,38,Anal Cancer,Anal Squamous Cell Carcinoma,76,ANSC,16.03,1:DECEASED,1,Metastatic,Matched,2.566666667,Anus,Female,COLO,Lymphatic System,Lymph Node,0,NA,NA,NA,NA,No,NA,30,NA,NA,NA,NA,NA,NA,NA
13904,58,Colorectal Cancer,Colon Adenocarcinoma,49,COAD,18.5,1:DECEASED,1,Metastatic,Matched,1.633333333,Colon,Male,COLO,Liver,Liver,21,NA,NA,NA,NA,No,NA,29,NA,NA,NA,NA,NA,NA,NA
13931,33,Hepatobiliary Cancer,Cholangiocarcinoma,22,CHOL,9.13,1:DECEASED,1,Metastatic,Matched,0.7666666667,Bile Duct,Female,CHOL,Liver,Liver,33,NA,NA,NA,NA,No,NA,50,NA,NA,NA,NA,NA,NA,NA
13947,38,Appendiceal Cancer,Appendiceal Adenocarcinoma,124,APAD,36.63,1:DECEASED,1,Metastatic,Matched,4.166666667,Appendix,Female,COLO,Liver,Liver,36,NA,NA,NA,NA,No,NA,81,NA,NA,NA,NA,NA,NA,NA
14231,54,Breast Cancer,Breast Invasive Ductal Carcinoma,21,IDC,4.76,1:DECEASED,1,Local Recurrence,Matched,0.7333333333,Breast,Female,BRCA,Chest Wall,Chest wall,34,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
14232,63,Colorectal Cancer,Colon Adenocarcinoma,105,COAD,23.36,1:DECEASED,1,Metastatic,Matched,3.5,Colon,Male,COLO,Liver,Liver,16,NA,NA,NA,NA,No,NA,73,NA,NA,NA,NA,NA,NA,NA
14446,84,Pancreatic Cancer,Pancreatic Adenocarcinoma,14,PAAD,10.91,1:DECEASED,1,Local Recurrence,Matched,0.4666666667,Pancreas,Female,PANC,Pancreas,Pancreas,2,NA,NA,NA,NA,No,NA,44,NA,NA,NA,NA,NA,NA,NA
14498,61,Salivary Gland Cancer,Salivary Carcinoma,104,SACA,34.92,1:DECEASED,1,Local Recurrence,Matched,3.5,Salivary Gland,Female,SECR,Lymphatic System,Lymph Node,25,NA,NA,NA,NA,No,NA,62,NA,NA,NA,NA,NA,NA,NA
14519,52,Sex Cord Stromal Tumor,Granulosa Cell Tumor,23,GRCT,163.76,1:DECEASED,1,Local Recurrence,Matched,0.7666666667,Ovary,Female,MISC,Soft Tissue,Pelvis,7,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
14891,46,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,236,LUAD,57,1:DECEASED,1,Local Recurrence,Matched,8.1,Lung,Female,LUNG,Respiratory System,Lung,19,Nivolumab,Mixed,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,46,0.04402036,0.314420901,0,0.251557554,0.049403796,0,0.044815315
15122,48,Breast Cancer,Breast Invasive Lobular Carcinoma,29,ILC,67.67,1:DECEASED,1,Metastatic,Matched,0.9666666667,Breast,Female,BRCA,Chest Wall,Chest wall,15,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
15123,53,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,110,LUAD,14.98,1:DECEASED,1,Metastatic,Matched,3.866666667,Lung,Female,LUNG,Lymphatic System,Lymph Node,40,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
15148,58,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,151,LUSC,40.47,1:DECEASED,1,Local Recurrence,Matched,5.133333333,Lung,Male,LUNG,Respiratory System,Lung,35,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
15227,50,Breast Cancer,Breast Invasive Ductal Carcinoma,28,IDC,24.15,1:DECEASED,1,Metastatic,Matched,1,Breast,Female,BRCA,Liver,Liver,65,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
15268,42,Non-Small Cell Lung Cancer,Adenoid Cystic Carcinoma of the Lung,20,LUACC,85.78,1:DECEASED,1,Local Recurrence,Matched,0.6666666667,Lung,Male,SECR,Respiratory System,Trachea,11,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
15844,48,Breast Cancer,Breast Invasive Ductal Carcinoma,244,IDC,141.29,1:DECEASED,1,Metastatic,Matched,8.133333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,36,NA,NA,NA,NA,No,NA,47,NA,NA,NA,NA,NA,NA,NA
16385,44,Pancreatic Cancer,Pancreatic Adenocarcinoma,30,PAAD,11.66,1:DECEASED,1,Metastatic,Matched,1,Pancreas,Male,PANC,Liver,Liver,24,NA,NA,NA,NA,No,NA,24,NA,NA,NA,NA,NA,NA,NA
16500,68,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,23,LUAD,23.65,1:DECEASED,1,Metastatic,Matched,0.7666666667,Lung,Male,LUNG,Liver,Liver,31,NA,NA,NA,NA,No,NA,43,NA,NA,NA,NA,NA,NA,NA
16501,61,Breast Cancer,Epithelial Type Metaplastic Breast Cancer,105,EMBC,16.46,1:DECEASED,1,Metastatic,Matched,3.533333333,Breast,Female,BRCA,Skin,Skin,62,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
16689,53,Breast Cancer,Metaplastic Breast Cancer,157,MBC,92.48,1:DECEASED,1,Metastatic,Matched,5.3,Breast,Female,BRCA,Respiratory System,Lung,63,NA,NA,NA,NA,No,NA,60,NA,NA,NA,NA,NA,NA,NA
16949,51,Prostate Cancer,Prostate Adenocarcinoma,39,PRAD,16.62,1:DECEASED,1,Metastatic,Matched,1.366666667,Prostate,Male,PRAD,Liver,Liver,52,NA,NA,NA,NA,No,NA,60,NA,NA,NA,NA,NA,NA,NA
17284,64,Mature T and NK Neoplasms,"Peripheral T-Cell lymphoma, NOS",NA,PTCL,38.47,1:DECEASED,1,Metastatic,Matched,0,NA,Female,LYMP,Skin,Skin,0,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
17557,66,Ovarian Cancer,High-Grade Serous Ovarian Cancer,240,HGSOC,56.24,1:DECEASED,1,Metastatic,Matched,8.233333333,Ovary,Female,OV,Reproductive System,Vagina,48,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
17584,36,Breast Cancer,Breast Invasive Ductal Carcinoma,63,IDC,30.85,1:DECEASED,1,Metastatic,Matched,2.133333333,Breast,Female,BRCA,Liver,Liver,2,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
17827,65,Endometrial Cancer,Uterine Endometrioid Carcinoma,498,UEC,61.89,0:LIVING,1,Metastatic,Matched,16.9,Uterus,Female,UCEC,Lymphatic System,Lymph Node,1,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
18153,42,Glioma,Anaplastic Oligodendroglioma,42,AODG,210.35,0:LIVING,1,Local Recurrence,Matched,1.4,NA,Male,CNS-PNS,Brain,Brain,8,NA,NA,NA,NA,No,NA,84,NA,NA,NA,NA,NA,NA,NA
18154,39,Breast Cancer,Breast Invasive Ductal Carcinoma,82,IDC,43.73,1:DECEASED,1,Metastatic,Matched,2.833333333,Breast,Female,BRCA,Liver,Liver,52,NA,NA,NA,NA,No,NA,63,NA,NA,NA,NA,NA,NA,NA
18228,64,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,79,LUAD,19.61,1:DECEASED,1,Local Recurrence,Matched,2.7,Lung,Female,LUNG,Chest Wall,Pleura,19,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
18568,34,Soft Tissue Sarcoma,Well-Differentiated Liposarcoma,11,WDLS,72.34,1:DECEASED,1,Local Recurrence,Matched,0.3666666667,NA,Female,SARC,Abdomen,Rectroperitoneum,0,NA,NA,NA,NA,No,NA,72,NA,NA,NA,NA,NA,NA,NA
18624,47,"Skin Cancer, Non-Melanoma",Sweat Gland Carcinoma/Apocrine Eccrine Carcinoma,48,AECA,62.09,1:DECEASED,1,Metastatic,Matched,1.666666667,Breast,Female,SECR,Chest Wall,Chest wall,1,Nivolumab,Stable disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,40,0,0.087723858,0,0.029652055,0.037388283,0,0.007902041
18625,58,Breast Cancer,Breast Invasive Ductal Carcinoma,33,IDC,37.09,1:DECEASED,1,Metastatic,Matched,1.1,Breast,Female,BRCA,Liver,Liver,38,NA,NA,NA,NA,No,NA,86,NA,NA,NA,NA,NA,NA,NA
18650,31,Mesothelioma,Peritoneal Mesothelioma,12,PEMESO,7,1:DECEASED,1,Local Recurrence,Matched,0.4,Pleura,Female,LUNG,Reproductive System,Omentum,33,NA,NA,NA,NA,No,NA,57,NA,NA,NA,NA,NA,NA,NA
18843,19,Adrenocortical Carcinoma,Adrenocortical Carcinoma,63,ACC,8.97,1:DECEASED,1,Local Recurrence,Matched,2.166666667,Adrenal,Male,ACC,Adrenal Gland,Adrenal,7,NA,NA,NA,NA,No,NA,86,NA,NA,NA,NA,NA,NA,NA
18844,66,Mesothelioma,Peritoneal Mesothelioma,283,PEMESO,63.44,0:LIVING,1,Local Recurrence,Matched,9.566666667,Pleura,Female,LUNG,Intestine,Colon,1,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
18880,60,Breast Cancer,Breast Invasive Ductal Carcinoma,50,IDC,48.95,1:DECEASED,1,Metastatic,Matched,1.733333333,Breast,Female,BRCA,Liver,Liver,27,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
19512,46,Breast Cancer,Breast Invasive Ductal Carcinoma,51,IDC,77.46,1:DECEASED,1,Metastatic,Matched,1.733333333,Breast,Female,BRCA,Liver,Liver,21,NA,NA,NA,NA,No,NA,76,NA,NA,NA,NA,NA,NA,NA
19652,56,Ovarian Cancer,Serous Ovarian Cancer,67,SOC,24.15,1:DECEASED,1,Metastatic,Matched,2.3,Ovary,Female,OV,Breast,Breast,4,NA,NA,NA,NA,No,NA,29,NA,NA,NA,NA,NA,NA,NA
19661,62,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,71,LUAD,46.62,1:DECEASED,1,Metastatic,Matched,2.433333333,Lung,Female,LUNG,Reproductive System,Omentum,8,NA,NA,NA,NA,No,NA,64,NA,NA,NA,NA,NA,NA,NA
19843,60,Breast Cancer,Breast Invasive Ductal Carcinoma,277,IDC,36.4,1:DECEASED,1,Metastatic,Matched,9.5,Breast,Female,BRCA,Breast,Breast,55,NA,NA,NA,NA,No,NA,69,NA,NA,NA,NA,NA,NA,NA
20034,61,Breast Cancer,Breast Invasive Ductal Carcinoma,194,IDC,39.55,1:DECEASED,1,Metastatic,Matched,6.566666667,Breast,Female,BRCA,Soft Tissue,Neck mass,45,NA,NA,NA,NA,No,NA,82,NA,NA,NA,NA,NA,NA,NA
20115,51,Breast Cancer,Breast Invasive Ductal Carcinoma,104,IDC,84.3,1:DECEASED,1,Metastatic,Matched,3.666666667,Breast,Female,BRCA,Chest Wall,Chest wall,18,NA,NA,NA,NA,No,NA,63,NA,NA,NA,NA,NA,NA,NA
20600,70,Hepatobiliary Cancer,Cholangiocarcinoma,60,CHOL,20.7,1:DECEASED,1,Metastatic,Matched,2,Bile Duct,Male,CHOL,Abdomen,Peritoneum,17,NA,NA,NA,NA,No,NA,84,NA,NA,NA,NA,NA,NA,NA
20794,57,Soft Tissue Sarcoma,Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma,106,MFH,9.23,1:DECEASED,1,Metastatic,Matched,3.566666667,NA,Female,SARC,Respiratory System,Lung,32,NA,NA,NA,NA,No,NA,73,NA,NA,NA,NA,NA,NA,NA
20800,39,Glioma,Oligodendroglioma,34,ODG,129.5,1:DECEASED,1,Local Recurrence,Matched,1.1,NA,Female,CNS-PNS,Brain,Brain,24,NA,NA,NA,NA,No,NA,81,NA,NA,NA,NA,NA,NA,NA
20801,57,Breast Cancer,Breast Invasive Ductal Carcinoma,112,IDC,37.61,1:DECEASED,1,Metastatic,Matched,3.8,Breast,Female,BRCA,Respiratory System,lung,55,NA,NA,NA,NA,No,NA,59,NA,NA,NA,NA,NA,NA,NA
21098,65,Soft Tissue Sarcoma,Dedifferentiated Liposarcoma,36,DDLS,39.68,1:DECEASED,1,Local Recurrence,Matched,1.2,NA,Male,SARC,Soft Tissue,Hip,0,NA,NA,NA,NA,No,NA,72,NA,NA,NA,NA,NA,NA,NA
21186,52,Breast Cancer,Breast Invasive Ductal Carcinoma,25,IDC,6.9,1:DECEASED,1,Metastatic,Matched,0.8333333333,Breast,Female,BRCA,Chest Wall,Chest wall,2,NA,NA,NA,NA,No,NA,20,NA,NA,NA,NA,NA,NA,NA
21188,40,Ovarian Cancer,Low-Grade Serous Ovarian Cancer,15,LGSOC,70.34,1:DECEASED,1,Metastatic,Matched,0.5,Ovary,Female,OV,Abdomen,Abdominal Wall,9,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
21347,50,Breast Cancer,Breast Invasive Ductal Carcinoma,32,IDC,54.5,1:DECEASED,1,Metastatic,Matched,1.1,Breast,Female,BRCA,Liver,Liver,17,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
21392,58,Ovarian Cancer,High-Grade Serous Ovarian Cancer,54,HGSOC,49.41,1:DECEASED,1,Metastatic,Matched,1.8,Ovary,Female,OV,Lymphatic System,Lymph Node,41,Monalizumab,Physician assessed SD,No durable clinical benefit,Mut per Mb < 10,Yes,NKG2A,42,0.013406019,0.12572148,0,0.045584137,0.030905518,0.014124359,0.050947475
21404,59,Small Bowel Cancer,Duodenal Adenocarcinoma,19,DA,47.96,1:DECEASED,1,Metastatic,Matched,0.7,Duodenum,Female,COLO,Lymphatic System,Lymph Node,0,NA,NA,NA,NA,No,NA,17,NA,NA,NA,NA,NA,NA,NA
21516,30,Melanoma,Melanoma,139,MEL,66.62,1:DECEASED,1,Local Recurrence,Matched,4.833333333,Skin,Female,SKCM,Skin,Skin,11,Ipilimumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,CTLA-4,55,0,0.131195662,0,0.059554978,0.030353309,0,0.021610508
21720,44,Breast Cancer,Breast Invasive Ductal Carcinoma,55,IDC,76.35,0:LIVING,1,Metastatic,Matched,1.866666667,Breast,Female,BRCA,Lymphatic System,Lymph Node,24,NA,NA,NA,NA,No,NA,69,NA,NA,NA,NA,NA,NA,NA
21721,50,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,29,LUAD,54.7,0:LIVING,1,Metastatic,Matched,0.9666666667,Lung,Female,LUNG,Lymphatic System,Lymph Node,17,NA,NA,NA,NA,No,NA,61,NA,NA,NA,NA,NA,NA,NA
21774,61,Breast Cancer,Breast Invasive Ductal Carcinoma,144,IDC,26.15,1:DECEASED,1,Metastatic,Matched,4.8,Breast,Female,BRCA,Chest Wall,Chest wall,73,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
21932,63,Colorectal Cancer,Colon Adenocarcinoma,81,COAD,26.05,1:DECEASED,1,Local Recurrence,Matched,2.7,Colon,Female,COLO,Soft Tissue,Pelvic Mass,13,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
21933,50,Breast Cancer,Breast Invasive Ductal Carcinoma,85,IDC,103.88,1:DECEASED,1,Metastatic,Matched,2.866666667,Breast,Female,BRCA,Chest Wall,Chest wall,23,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
22186,55,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,75,LUAD,76.18,1:DECEASED,1,Metastatic,Matched,2.5,Lung,Female,LUNG,Respiratory System,Lung,36,Atezolizumab,Stable disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,41,0,0.185820575,0,0.010520733,0.034752746,0,0.036226927
22244,24,Bone Cancer,Ewing Sarcoma,57,ES,85.45,1:DECEASED,1,Metastatic,Matched,2,NA,Female,SARC,Spine,Spine,15,NA,NA,NA,NA,No,NA,54,NA,NA,NA,NA,NA,NA,NA
22254,61,Anal Cancer,Anal Squamous Cell Carcinoma,113,ANSC,44.97,1:DECEASED,1,Metastatic,Matched,3.866666667,Anus,Female,COLO,Chest Wall,Chest wall,9,NA,NA,NA,NA,No,NA,29,NA,NA,NA,NA,NA,NA,NA
22256,46,Breast Cancer,Breast Invasive Ductal Carcinoma,111,IDC,27.99,1:DECEASED,1,Local Recurrence,Matched,3.833333333,Breast,Female,BRCA,Breast,Breast,30,NA,NA,NA,NA,No,NA,62,NA,NA,NA,NA,NA,NA,NA
22415,67,Breast Cancer,Breast Invasive Lobular Carcinoma,35,ILC,121.52,1:DECEASED,1,Metastatic,Matched,1.2,Breast,Female,BRCA,Soft Tissue,Upper Back Mass,9,NA,NA,NA,NA,No,NA,73,NA,NA,NA,NA,NA,NA,NA
22499,60,Breast Cancer,Breast Invasive Ductal Carcinoma,52,IDC,4.83,1:DECEASED,1,Metastatic,Matched,1.733333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,37,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
22592,54,Breast Cancer,Breast Invasive Ductal Carcinoma,71,IDC,13.96,1:DECEASED,1,Metastatic,Matched,2.466666667,Breast,Female,BRCA,Chest Wall,Chest wall,42,NA,NA,NA,NA,No,NA,52,NA,NA,NA,NA,NA,NA,NA
22593,54,Cervical Cancer,Cervical Adenoid Cystic Carcinoma,23,CACC,61.89,1:DECEASED,1,Metastatic,Matched,0.8333333333,unknown,Female,SECR,Soft Tissue,Rectus Muscle,0,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
22595,59,Breast Cancer,Breast Invasive Ductal Carcinoma,39,IDC,86.89,1:DECEASED,1,Metastatic,Matched,1.366666667,Breast,Female,BRCA,Lymphatic System,Lymph Node,29,NA,NA,NA,NA,No,NA,81,NA,NA,NA,NA,NA,NA,NA
22597,75,Breast Cancer,Breast Invasive Ductal Carcinoma,68,IDC,54.34,0:LIVING,1,Metastatic,Matched,2.3,Breast,Female,BRCA,Liver,Liver,31,NA,NA,NA,NA,No,NA,75,NA,NA,NA,NA,NA,NA,NA
23162,45,Cervical Cancer,Cervical Adenocarcinoma In Situ,29,CEAIS,12.32,0:LIVING,1,Metastatic,Matched,0.9666666667,NA,Female,CERV,Lymphatic System,Lymph Node,43,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
23187,50,Cervical Cancer,Cervical Adenocarcinoma In Situ,404,CEAIS,45.99,1:DECEASED,1,Local Recurrence,Matched,13.46666667,NA,Female,CERV,Reproductive System,Cervix,21,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
23189,22,Bone Cancer,Osteosarcoma,36,OS,25.76,1:DECEASED,1,Metastatic,Matched,1.2,NA,Male,SARC,Respiratory System,Lung,11,NA,NA,NA,NA,No,NA,75,NA,NA,NA,NA,NA,NA,NA
23205,62,Mature B-Cell Neoplasms,Follicular Lymphoma,71,FL,48.75,0:LIVING,1,Local Recurrence,Matched,2.5,NA,Female,LYMP,Lymphatic System,Lymph Node,3,NA,NA,NA,NA,No,NA,61,NA,NA,NA,NA,NA,NA,NA
23237,42,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,1,LUAD,38.47,1:DECEASED,1,Metastatic,Matched,0.03333333333,Lung,Female,LUNG,Liver,Liver,0,Nivolumab,Not evaluable,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,20,0,0.305095522,0,0.236571116,0.090777172,0,0.125176726
23238,44,Ovarian Cancer,Low-Grade Serous Ovarian Cancer,59,LGSOC,36.96,1:DECEASED,1,Metastatic,Matched,1.933333333,Ovary,Female,OV,Abdomen,Abdominal Mass,47,NA,NA,NA,NA,No,NA,66,NA,NA,NA,NA,NA,NA,NA
23239,66,Melanoma,Uveal Melanoma,19,UM,78.84,0:LIVING,1,Metastatic,Matched,0.7,Eye,Male,UVM,Liver,Liver,24,NA,NA,NA,NA,No,NA,84,NA,NA,NA,NA,NA,NA,NA
23315,55,Colorectal Cancer,Colon Adenocarcinoma,84,COAD,35.15,1:DECEASED,1,Metastatic,Matched,2.866666667,Colon,Male,COLO,Liver,Liver,33,NA,NA,NA,NA,No,NA,48,NA,NA,NA,NA,NA,NA,NA
23344,57,Endometrial Cancer,Endometrial Carcinoma,54,UCEC,96.88,1:DECEASED,1,Metastatic,Matched,1.8,NA,Female,UCEC,Lymphatic System,Lymph Node,2,NA,NA,NA,NA,No,NA,72,NA,NA,NA,NA,NA,NA,NA
23401,34,Bladder Cancer,Bladder Adenocarcinoma,87,BLAD,12.09,1:DECEASED,1,Metastatic,Matched,2.933333333,Bladder,Female,BLCA,Abdomen,Peritoneal Mass,47,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
23411,66,Soft Tissue Sarcoma,Leiomyosarcoma,52,LMS,33.25,1:DECEASED,1,Metastatic,Matched,1.8,NA,Female,SARC,Liver,Liver,26,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
23453,61,Colorectal Cancer,Colon Adenocarcinoma,58,COAD,41.72,1:DECEASED,1,Metastatic,Matched,2,Colon,Male,COLO,Liver,Liver,22,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
23454,62,Breast Cancer,Breast Invasive Ductal Carcinoma,28,IDC,30.06,1:DECEASED,1,Metastatic,Matched,0.9333333333,Breast,Female,BRCA,Liver,Liver,5,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
23673,33,Colorectal Cancer,Colon Adenocarcinoma,32,COAD,33.25,1:DECEASED,1,Local Recurrence,Matched,1.066666667,Colon,Male,COLO,Soft Tissue,Rectum,9,NA,NA,NA,NA,No,NA,31,NA,NA,NA,NA,NA,NA,NA
23674,66,Colorectal Cancer,Colon Adenocarcinoma,1978,COAD,79.3,0:LIVING,1,Metastatic,Matched,66.9,Colon,Female,COLO,Lymphatic System,Lymph Node,2,Ipilimumab/nivolumab,Physician assessed PR,Durable clinical benefit,Mut per Mb >= 10,Yes,PD-L1/CTLA-4,63,0.05827791,0.017900298,0,0.149700983,0.052959989,0,0.006934784
23675,52,Breast Cancer,Breast Invasive Ductal Carcinoma,42,IDC,31.08,1:DECEASED,1,Metastatic,Matched,1.433333333,Breast,Female,BRCA,Breast,Breast,28,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
23676,51,Colorectal Cancer,Colon Adenocarcinoma,102,COAD,62.16,1:DECEASED,1,Metastatic,Matched,3.433333333,Colon,Female,COLO,Respiratory System,Lung,25,NA,NA,NA,NA,No,NA,50,NA,NA,NA,NA,NA,NA,NA
23701,31,Breast Cancer,Breast Invasive Ductal Carcinoma,91,IDC,23.09,1:DECEASED,1,Metastatic,Matched,3.133333333,Breast,Female,BRCA,Liver,Liver,55,"Gemcitabine, Vinorelbine, Pembrolizumab (Arizona)",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1/Chemo,48,0.008032332,0.115715506,0,0,0.00836914,0.000375829,0.010620837
23706,65,Breast Cancer,Breast Invasive Ductal Carcinoma,37,IDC,60.22,1:DECEASED,1,Metastatic,Matched,1.233333333,Breast,Female,BRCA,Liver,Liver,19,NA,NA,NA,NA,No,NA,83,NA,NA,NA,NA,NA,NA,NA
23736,66,Breast Cancer,Breast Invasive Ductal Carcinoma,78,IDC,11.2,1:DECEASED,1,Metastatic,Matched,2.633333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,53,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
23737,81,Breast Cancer,Breast Invasive Ductal Carcinoma,171,IDC,51.71,0:LIVING,1,Metastatic,Matched,5.733333333,Breast,Female,BRCA,Soft Tissue,Arm,36,NA,NA,NA,NA,No,NA,41,NA,NA,NA,NA,NA,NA,NA
23738,62,Soft Tissue Sarcoma,Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma,67,MFH,9.2,1:DECEASED,1,Metastatic,Matched,2.266666667,NA,Male,SARC,Lymphatic System,Lymph Node,34,NA,NA,NA,NA,No,NA,87,NA,NA,NA,NA,NA,NA,NA
23739,61,Anal Cancer,Anal Squamous Cell Carcinoma,119,ANSC,24.51,1:DECEASED,1,Metastatic,Matched,4,Anus,Male,COLO,Liver,Liver,19,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
23764,60,Soft Tissue Sarcoma,Leiomyosarcoma,21,LMS,43.23,1:DECEASED,1,Metastatic,Matched,0.7,NA,Male,SARC,Liver,Liver,1,Atezolizumab,Stable disease,Durable clinical benefit,Mut per Mb < 10,Yes,PD-1,55,0.209711476,0.548388962,0,0.296018293,0.003724425,0,0.120707002
23802,59,Head and Neck Cancer,Odontogenic Carcinoma,38,ODGC,19.42,1:DECEASED,1,Local Recurrence,Matched,1.266666667,Oral Cavity,Male,HNSC,Head & Neck,Maxilla,14,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
23805,79,Melanoma,Mucosal Melanoma of the Vulva/Vagina,37,VMM,12.39,1:DECEASED,1,Metastatic,Matched,1.233333333,Vulva,Female,SKCM,Lymphatic System,Lymph Node,34,NA,NA,NA,NA,No,NA,83,NA,NA,NA,NA,NA,NA,NA
23808,66,Melanoma,Melanoma,330,MEL,49.41,0:LIVING,1,Metastatic,Matched,11.06666667,Skin,Female,SKCM,Lymphatic System,Lymph Node,38,Pembrolizumab,Physician assessed SD,Durable clinical benefit,Mut per Mb >= 10,Yes,PD-1,90,0.006577166,0.050951542,0,0.068785885,0.036953052,0,0
23940,48,Vaginal Cancer,Squamous Cell Carcinoma of the Vulva/Vagina,60,VSC,18.3,1:DECEASED,1,Metastatic,Matched,2.1,NA,Female,MISC,Lymphatic System,Lymph Node,27,NA,NA,NA,NA,No,NA,67,NA,NA,NA,NA,NA,NA,NA
24045,75,Breast Cancer,Breast Invasive Ductal Carcinoma,65,IDC,27.3,1:DECEASED,1,Metastatic,Matched,2.2,Breast,Female,BRCA,Liver,Liver,32,NA,NA,NA,NA,No,NA,62,NA,NA,NA,NA,NA,NA,NA
24077,59,Colorectal Cancer,Colon Adenocarcinoma,103,COAD,37.06,1:DECEASED,1,Metastatic,Matched,3.5,Colon,Male,COLO,Liver,Liver,11,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
24176,69,Gastrointestinal Neuroendocrine Tumor,High-Grade Neuroendocrine Carcinoma of the Colon and Rectum,21,HGNEC,140.67,1:DECEASED,1,Metastatic,Matched,0.7333333333,Rectum,Male,COLO,Soft Tissue,Lower Back,9,NA,NA,NA,NA,No,NA,81,NA,NA,NA,NA,NA,NA,NA
24177,61,Vaginal Cancer,Vaginal Adenocarcinoma,254,VA,30.68,1:DECEASED,1,Metastatic,Matched,8.533333333,NA,Female,MISC,Lymphatic System,Lymph Node,23,NA,NA,NA,NA,No,NA,68,NA,NA,NA,NA,NA,NA,NA
24229,46,Pancreatic Cancer,Pancreatic Neuroendocrine Tumor,104,PANET,7.75,1:DECEASED,1,Metastatic,Matched,3.566666667,Pancreas,Female,PANC,Liver,Liver,31,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
24243,34,Pancreatic Cancer,Pancreatic Adenocarcinoma,18,PAAD,6.93,1:DECEASED,1,Metastatic,Matched,0.6,Pancreas,Male,PANC,Liver,Liver,18,NA,NA,NA,NA,No,NA,50,NA,NA,NA,NA,NA,NA,NA
24294,59,Soft Tissue Sarcoma,Leiomyosarcoma,15,LMS,60.28,1:DECEASED,1,Metastatic,Matched,0.5,NA,Male,SARC,Soft Tissue,Flank Mass,46,Atezolizumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1,87,0,0,0,0,0,0,0
24295,52,Mesothelioma,Peritoneal Mesothelioma,86,PEMESO,7.33,1:DECEASED,1,Local Recurrence,Matched,2.9,Pleura,Female,LUNG,Abdomen,Abdominal Mass,11,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
24358,48,Esophagogastric Cancer,Adenocarcinoma of the Gastroesophageal Junction,74,GEJ,5.58,1:DECEASED,1,Metastatic,Matched,2.5,Gastroesophageal Junction,Male,ESCA,Liver,Liver,31,NA,NA,NA,NA,No,NA,40,NA,NA,NA,NA,NA,NA,NA
24359,67,"Skin Cancer, Non-Melanoma",Porocarcinoma/Spiroadenocarcinoma,29,POCA,27.83,1:DECEASED,1,Metastatic,Matched,0.9666666667,NA,Male,MISC,Lymphatic System,Lymph Node,14,NA,NA,NA,NA,No,NA,66,NA,NA,NA,NA,NA,NA,NA
24363,47,Pancreatic Cancer,Pancreatic Adenocarcinoma,57,PAAD,16.82,1:DECEASED,1,Metastatic,Matched,1.933333333,Pancreas,Female,PANC,Liver,Liver,15,Nivolumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,51,0,0.249638803,0,0.039448732,0.003938573,0,0.030120283
24423,51,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,68,LUAD,22.77,1:DECEASED,1,Metastatic,Matched,2.3,Lung,Female,LUNG,Liver,Liver,40,NA,NA,NA,NA,No,NA,79,NA,NA,NA,NA,NA,NA,NA
24424,65,Colorectal Cancer,Colon Adenocarcinoma,44,COAD,60.05,1:DECEASED,1,Local Recurrence,Matched,1.5,Colon,Female,COLO,Intestine,Colon,25,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
24464,67,Thyroid Cancer,Medullary Thyroid Cancer,27,THME,47.34,0:LIVING,1,Metastatic,Matched,0.9333333333,Thyroid,Male,THCA,Lymphatic System,Lymph Node,7,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
24465,58,Endometrial Cancer,Other Uterine Tumor,14,OUTT,18.89,1:DECEASED,1,Metastatic,Matched,0.4666666667,Uterus,Female,MISC,Abdomen,Abdominal Mass,6,NA,NA,NA,NA,No,NA,94,NA,NA,NA,NA,NA,NA,NA
24550,61,Breast Cancer,Breast Invasive Ductal Carcinoma,32,IDC,2.17,1:DECEASED,1,Metastatic,Matched,1.1,Breast,Female,BRCA,Liver,Liver,32,NA,NA,NA,NA,No,NA,34,NA,NA,NA,NA,NA,NA,NA
24838,70,Breast Cancer,Breast Invasive Ductal Carcinoma,54,IDC,32.23,1:DECEASED,1,Metastatic,Matched,1.9,Breast,Female,BRCA,Liver,Liver,16,NA,NA,NA,NA,No,NA,67,NA,NA,NA,NA,NA,NA,NA
25027,73,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,120,LUAD,12.91,1:DECEASED,1,Metastatic,Matched,4.133333333,Lung,Male,LUNG,Lymphatic System,Lymph Node,1,NA,NA,NA,NA,No,NA,32,NA,NA,NA,NA,NA,NA,NA
25134,54,Ovarian Cancer,Clear Cell Ovarian Cancer,39,CCOV,39.72,0:LIVING,1,Local Recurrence,Matched,1.266666667,Ovary,Female,OV,Reproductive System,Ovary,6,NA,NA,NA,NA,No,NA,48,NA,NA,NA,NA,NA,NA,NA
25315,60,Breast Cancer,Epithelial Type Metaplastic Breast Cancer,52,EMBC,9,1:DECEASED,1,Metastatic,Matched,1.766666667,Breast,Female,BRCA,Lymphatic System,Lymph Node,27,NA,NA,NA,NA,No,NA,78,NA,NA,NA,NA,NA,NA,NA
25317,47,Hepatobiliary Cancer,Cholangiocarcinoma,27,CHOL,22.47,1:DECEASED,1,Metastatic,Matched,0.9,Bile Duct,Male,CHOL,Soft Tissue,Scapula Mass,19,NA,NA,NA,NA,No,NA,82,NA,NA,NA,NA,NA,NA,NA
25318,67,Pancreatic Cancer,Pancreatic Neuroendocrine Tumor,158,PANET,9.13,1:DECEASED,1,Metastatic,Matched,5.333333333,Pancreas,Male,PANC,Liver,Liver,23,NA,NA,NA,NA,No,NA,86,NA,NA,NA,NA,NA,NA,NA
25352,79,Soft Tissue Sarcoma,Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma,72,MFH,39.62,1:DECEASED,1,Metastatic,Matched,2.4,NA,Male,SARC,Abdomen,Abdominal Mass,60,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
25356,66,Breast Cancer,Breast Invasive Ductal Carcinoma,194,IDC,12.45,1:DECEASED,1,Metastatic,Matched,6.7,Breast,Female,BRCA,Liver,Liver,33,NA,NA,NA,NA,No,NA,78,NA,NA,NA,NA,NA,NA,NA
25358,64,Breast Cancer,Metaplastic Breast Cancer,110,MBC,14.16,1:DECEASED,1,Metastatic,Matched,3.7,Breast,Female,BRCA,Chest Wall,Chest wall,38,NA,NA,NA,NA,No,NA,51,NA,NA,NA,NA,NA,NA,NA
25419,49,Colorectal Cancer,Colon Adenocarcinoma,33,COAD,10.74,1:DECEASED,1,Metastatic,Matched,1.1,Colon,Male,COLO,Liver,Liver,5,Atezolizumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,34,0,0.143250621,0,0.096431302,0.002273626,0,0.061382512
25424,46,Colorectal Cancer,Colon Adenocarcinoma,51,COAD,43.96,1:DECEASED,1,Metastatic,Matched,1.733333333,Colon,Male,COLO,Liver,Liver,27,NA,NA,NA,NA,No,NA,76,NA,NA,NA,NA,NA,NA,NA
25426,60,Soft Tissue Sarcoma,Pleomorphic Liposarcoma,36,PLLS,20.76,1:DECEASED,1,Metastatic,Matched,1.266666667,NA,Female,SARC,Respiratory System,Lung,40,NA,NA,NA,NA,No,NA,52,NA,NA,NA,NA,NA,NA,NA
25435,59,Small Cell Lung Cancer,Combined Small Cell Lung Carcinoma,20,CSCLC,10.74,1:DECEASED,1,Metastatic,Matched,0.6666666667,Lung,Male,LUNG,Liver,Liver,12,NA,NA,NA,NA,No,NA,59,NA,NA,NA,NA,NA,NA,NA
25436,67,Esophagogastric Cancer,Adenosquamous Carcinoma of the Stomach,236,STAS,18.89,1:DECEASED,1,Metastatic,Matched,7.933333333,Stomach,Male,STAD,Liver,Liver,28,NA,NA,NA,NA,No,NA,57,NA,NA,NA,NA,NA,NA,NA
25437,77,Colorectal Cancer,Colon Adenocarcinoma,99,COAD,44.38,0:LIVING,1,Metastatic,Matched,3.333333333,Colon,Male,COLO,Liver,Liver,27,NA,NA,NA,NA,No,NA,71,NA,NA,NA,NA,NA,NA,NA
25438,77,Esophagogastric Cancer,Esophageal Adenocarcinoma,5,ESCA,52.43,0:LIVING,1,Metastatic,Matched,0.1666666667,Esophagus,Male,ESCA,Chest Wall,Mediastinal Lesion,1,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
25439,65,Colorectal Cancer,Colon Adenocarcinoma,97,COAD,6.6,1:DECEASED,1,Metastatic,Matched,3.266666667,Colon,Male,COLO,Lymphatic System,Lymph Node,25,NA,NA,NA,NA,No,NA,54,NA,NA,NA,NA,NA,NA,NA
25440,54,Colorectal Cancer,Colon Adenocarcinoma,106,COAD,46.81,1:DECEASED,1,Metastatic,Matched,3.566666667,Colon,Female,COLO,Liver,Liver,22,NA,NA,NA,NA,No,NA,57,NA,NA,NA,NA,NA,NA,NA
25441,64,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,20,LUAD,5.98,0:LIVING,1,Local Recurrence,Matched,0.6666666667,Lung,Female,LUNG,Respiratory System,Lung,33,NA,NA,NA,NA,No,NA,49,NA,NA,NA,NA,NA,NA,NA
25483,74,Breast Cancer,Breast Invasive Ductal Carcinoma,19,IDC,53.58,1:DECEASED,1,Metastatic,Matched,0.6333333333,Breast,Female,BRCA,Chest Wall,Chest wall,1,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
25484,37,Soft Tissue Sarcoma,Myxoid/Round-Cell Liposarcoma,19,MRLS,44.25,0:LIVING,1,Metastatic,Matched,0.6333333333,NA,Male,SARC,Chest Wall,Chest wall,0,NA,NA,NA,NA,No,NA,85,NA,NA,NA,NA,NA,NA,NA
25494,69,Pancreatic Cancer,Pancreatic Adenocarcinoma,25,PAAD,5.62,1:DECEASED,1,Metastatic,Matched,0.8333333333,Pancreas,Female,PANC,Liver,Liver,1,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
25496,52,Pancreatic Cancer,Pancreatic Neuroendocrine Tumor,18,PANET,61.01,0:LIVING,1,Metastatic,Matched,0.6,Pancreas,Female,PANC,Liver,Liver,22,NA,NA,NA,NA,No,NA,79,NA,NA,NA,NA,NA,NA,NA
25497,59,Colorectal Cancer,Colon Adenocarcinoma,73,COAD,49.7,1:DECEASED,1,Metastatic,Matched,2.466666667,Colon,Male,COLO,Liver,Liver,16,NA,NA,NA,NA,No,NA,64,NA,NA,NA,NA,NA,NA,NA
25498,54,Colorectal Cancer,Colon Adenocarcinoma,117,COAD,22.27,1:DECEASED,1,Metastatic,Matched,3.9,Colon,Female,COLO,Liver,Liver,28,NA,NA,NA,NA,No,NA,63,NA,NA,NA,NA,NA,NA,NA
25500,51,Esophagogastric Cancer,Stomach Adenocarcinoma,36,STAD,12.98,1:DECEASED,1,Metastatic,Matched,1.2,Stomach,Female,STAD,Liver,Liver,10,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
25501,58,Hepatobiliary Cancer,Cholangiocarcinoma,8,CHOL,19.48,1:DECEASED,1,Metastatic,Matched,0.3,Bile Duct,Male,CHOL,Abdomen,Abdominal Wall,0,NA,NA,NA,NA,No,NA,25,NA,NA,NA,NA,NA,NA,NA
25535,39,Hepatobiliary Cancer,Intrahepatic Cholangiocarcinoma,31,IHCH,39.36,1:DECEASED,1,Metastatic,Matched,1.066666667,Bile Duct,Female,CHOL,Liver,Liver,1,NA,NA,NA,NA,No,NA,48,NA,NA,NA,NA,NA,NA,NA
25559,26,Thymic Tumor,Thymic Carcinoma,4,THYC,46.98,0:LIVING,1,Metastatic,Matched,0.1333333333,Thymus,Male,THYM,Chest Wall,Pleura,0,Atezolizumab,Partial response,Durable clinical benefit,Mut per Mb < 10,Yes,PD-1,36,0.21635406,0.253812308,0,0.768429286,0.225868889,0,0.146536429
25560,61,Esophagogastric Cancer,Esophageal Squamous Cell Carcinoma,45,ESCC,4.3,1:DECEASED,1,Unknown,Matched,1.533333333,Esophagus,Male,MISC,Soft Tissue,Neck mass,11,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
25572,58,Soft Tissue Sarcoma,"Round Cell Sarcoma, NOS",79,RCSNOS,17.28,1:DECEASED,1,Local Recurrence,Matched,2.666666667,NA,Female,SARC,Respiratory System,Lung,21,NA,NA,NA,NA,No,NA,92,NA,NA,NA,NA,NA,NA,NA
25582,62,Pancreatic Cancer,Pancreatic Adenocarcinoma,59,PAAD,6.77,1:DECEASED,1,Metastatic,Matched,1.933333333,Pancreas,Female,PANC,Liver,Liver,30,NA,NA,NA,NA,No,NA,49,NA,NA,NA,NA,NA,NA,NA
25583,68,Non-Small Cell Lung Cancer,Adenoid Cystic Carcinoma of the Lung,16,LUACC,199.87,0:LIVING,1,Metastatic,Matched,0.5333333333,Lung,Female,SECR,Respiratory System,Lung,3,NA,NA,NA,NA,No,NA,74,NA,NA,NA,NA,NA,NA,NA
25589,58,Anal Cancer,Anal Squamous Cell Carcinoma,312,ANSC,60.09,1:DECEASED,1,Metastatic,Matched,10.43333333,Anus,Female,COLO,Chest Wall,Chest wall,5,Nivolumab,Physician assessed PR,Durable clinical benefit,Mut per Mb >= 10,Yes,PD-1,76,0.016875538,0.185241132,0,0.157294524,0.084431354,0,0.056428679
25590,69,Colorectal Cancer,Colon Adenocarcinoma,216,COAD,59.23,1:DECEASED,1,Metastatic,Matched,7.466666667,Colon,Female,COLO,Liver,Liver,21,NA,NA,NA,NA,No,NA,63,NA,NA,NA,NA,NA,NA,NA
25593,32,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,143,LUAD,30.35,1:DECEASED,1,Metastatic,Matched,4.9,Lung,Female,LUNG,Liver,Liver,21,"Tremelimumab, Durvalumab, Pemetrexed, Carboplatin",Partial response,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1/CTLA-4/Chemo,61,0,0.073431091,0,0.048460822,0.033505957,0,0.057512033
25594,65,Esophagogastric Cancer,Stomach Adenocarcinoma,92,STAD,3.65,1:DECEASED,1,Metastatic,Matched,3.2,Stomach,Male,STAD,Liver,Liver,36,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
25603,67,Endometrial Cancer,Uterine Endometrioid Carcinoma,29,UEC,28.71,1:DECEASED,1,Metastatic,Matched,0.9666666667,Uterus,Female,UCEC,Lymphatic System,Lymph Node,29,Nivolumab +IDO1 inhibitor (BMS986205),Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1/IDO-1,55,0,0.243577843,0,0.154590178,0.068984862,0,0.025955633
25604,40,Germ Cell Tumor,Non-Seminomatous Germ Cell Tumor,56,NSGCT,179.24,1:DECEASED,1,Metastatic,Matched,1.933333333,NA,Male,MISC,Liver,Liver,34,Atezolizumab,Stable disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,57,0,0.037255729,0,0.018783564,0.009640601,0,0
25657,55,Endometrial Cancer,Uterine Endometrioid Carcinoma,436,UEC,19.32,1:DECEASED,1,Metastatic,Matched,14.8,Uterus,Female,UCEC,Abdomen,Abdominal Mass,0,NA,NA,NA,NA,No,NA,39,NA,NA,NA,NA,NA,NA,NA
25658,57,Colorectal Cancer,Colon Adenocarcinoma,110,COAD,62.91,1:DECEASED,1,Metastatic,Matched,3.733333333,Colon,Female,COLO,Respiratory System,Lung,20,NA,NA,NA,NA,No,NA,57,NA,NA,NA,NA,NA,NA,NA
25662,40,Breast Cancer,Breast Invasive Ductal Carcinoma,35,IDC,3.06,1:DECEASED,1,Metastatic,Matched,1.2,Breast,Female,BRCA,Liver,Liver,33,NA,NA,NA,NA,No,NA,76,NA,NA,NA,NA,NA,NA,NA
25664,64,Pancreatic Cancer,Pancreatic Adenocarcinoma,37,PAAD,11.01,1:DECEASED,1,Metastatic,Matched,1.3,Pancreas,Male,PANC,Liver,Liver,16,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
25719,63,Colorectal Cancer,Colon Adenocarcinoma,75,COAD,16.2,1:DECEASED,1,Metastatic,Matched,2.566666667,Colon,Male,COLO,Liver,Liver,4,NA,NA,NA,NA,No,NA,51,NA,NA,NA,NA,NA,NA,NA
25720,73,Prostate Cancer,Prostate Adenocarcinoma,44,PRAD,46.19,0:LIVING,1,Metastatic,Matched,1.5,Prostate,Male,PRAD,Liver,Liver,18,NA,NA,NA,NA,No,NA,71,NA,NA,NA,NA,NA,NA,NA
25721,55,Breast Cancer,Breast Invasive Ductal Carcinoma,334,IDC,24.11,1:DECEASED,1,Metastatic,Matched,11.23333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,38,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
25722,58,Bone Cancer,Chordoma,21,CHDM,31.11,1:DECEASED,1,Local Recurrence,Matched,0.8,NA,Male,SARC,Head & Neck,Skull Base,17,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
25731,63,Hepatobiliary Cancer,Cholangiocarcinoma,17,CHOL,18.82,1:DECEASED,1,Local Recurrence,Matched,0.6,Bile Duct,Female,CHOL,Liver,Liver,27,NA,NA,NA,NA,No,NA,59,NA,NA,NA,NA,NA,NA,NA
25744,54,Melanoma,Melanoma of Unknown Primary,89,MUP,6.77,1:DECEASED,1,Unknown,Matched,3.033333333,NA,Male,SKCM,Chest Wall,Chest wall,5,NA,NA,NA,NA,No,NA,75,NA,NA,NA,NA,NA,NA,NA
25751,63,Hepatobiliary Cancer,Cholangiocarcinoma,23,CHOL,10.84,1:DECEASED,1,Metastatic,Matched,0.8,Bile Duct,Female,CHOL,Liver,Liver,20,NA,NA,NA,NA,No,NA,41,NA,NA,NA,NA,NA,NA,NA
25752,66,Breast Cancer,Breast Invasive Ductal Carcinoma,58,IDC,35.48,1:DECEASED,1,Metastatic,Matched,2,Breast,Female,BRCA,Chest Wall,Chest wall,37,NA,NA,NA,NA,No,NA,63,NA,NA,NA,NA,NA,NA,NA
25753,58,Colorectal Cancer,Colon Adenocarcinoma,61,COAD,30.22,1:DECEASED,1,Metastatic,Matched,2.066666667,Colon,Male,COLO,Liver,Liver,21,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
25755,60,Colorectal Cancer,Colon Adenocarcinoma,80,COAD,27.07,1:DECEASED,1,Metastatic,Matched,2.7,Colon,Female,COLO,Liver,Liver,2,NA,NA,NA,NA,No,NA,41,NA,NA,NA,NA,NA,NA,NA
25766,36,Hepatobiliary Cancer,Hepatocellular Carcinoma,15,HCC,143.36,0:LIVING,1,Metastatic,Matched,0.5333333333,Liver,Female,HCC,Respiratory System,Lung,17,NA,NA,NA,NA,No,NA,34,NA,NA,NA,NA,NA,NA,NA
25767,50,Pancreatic Cancer,Pancreatic Adenocarcinoma,15,PAAD,13.73,1:DECEASED,1,Metastatic,Matched,0.5,Pancreas,Female,PANC,Liver,Liver,1,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
25768,66,Hepatobiliary Cancer,Hepatocellular Carcinoma,37,HCC,45.14,0:LIVING,1,Local Recurrence,Matched,1.266666667,Liver,Male,HCC,Liver,Liver,13,NA,NA,NA,NA,No,NA,76,NA,NA,NA,NA,NA,NA,NA
25777,52,Breast Cancer,Breast Invasive Ductal Carcinoma,229,IDC,3.68,1:DECEASED,1,Metastatic,Matched,7.733333333,Breast,Female,BRCA,Brain,Brain,56,NA,NA,NA,NA,No,NA,36,NA,NA,NA,NA,NA,NA,NA
25816,59,Colorectal Cancer,Colon Adenocarcinoma,55,COAD,57.16,0:LIVING,1,Metastatic,Matched,1.833333333,Colon,Female,COLO,Respiratory System,Lung,26,NA,NA,NA,NA,No,NA,49,NA,NA,NA,NA,NA,NA,NA
25890,61,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,42,LUAD,12.32,1:DECEASED,1,Metastatic,Matched,1.4,Lung,Female,LUNG,Liver,Liver,20,NA,NA,NA,NA,No,NA,26,NA,NA,NA,NA,NA,NA,NA
25899,67,Pancreatic Cancer,Pancreatic Adenocarcinoma,31,PAAD,7.92,1:DECEASED,1,Metastatic,Matched,1.066666667,Pancreas,Male,PANC,Liver,Liver,28,NA,NA,NA,NA,No,NA,26,NA,NA,NA,NA,NA,NA,NA
25901,66,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,47,LUAD,41.23,1:DECEASED,1,Local Recurrence,Matched,1.633333333,Lung,Male,LUNG,Respiratory System,Lung,22,NA,NA,NA,NA,No,NA,81,NA,NA,NA,NA,NA,NA,NA
25902,78,Breast Cancer,Breast Invasive Ductal Carcinoma,90,IDC,17.54,1:DECEASED,1,Metastatic,Matched,3.033333333,Breast,Female,BRCA,Liver,Liver,47,NA,NA,NA,NA,No,NA,78,NA,NA,NA,NA,NA,NA,NA
25921,62,Mesothelioma,"Pleural Mesothelioma, Epithelioid Type",9,PLEMESO,51.94,0:LIVING,1,Local Recurrence,Matched,0.3,Pleura,Male,LUNG,Chest Wall,Pleura,0,Nivolumab,Physician assessed PR,Durable clinical benefit,Mut per Mb < 10,Yes,PD-1,34,0,0.198402313,0,0.195354449,0.033746416,0.020996458,0.080320052
25923,52,Cervical Cancer,Endocervical Adenocarcinoma,18,ECAD,170.83,0:LIVING,1,Metastatic,Matched,0.6,NA,Female,CERV,Lymphatic System,Lymph Node,35,NA,NA,NA,NA,No,NA,26,NA,NA,NA,NA,NA,NA,NA
25958,68,Breast Cancer,Breast Invasive Ductal Carcinoma,16,IDC,8.8,1:DECEASED,1,Metastatic,Matched,0.5333333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,21,NA,NA,NA,NA,No,NA,38,NA,NA,NA,NA,NA,NA,NA
25959,67,Thyroid Cancer,Medullary Thyroid Cancer,48,THME,47.57,0:LIVING,1,Metastatic,Matched,1.633333333,Thyroid,Female,THCA,Breast,Breast,21,NA,NA,NA,NA,No,NA,94,NA,NA,NA,NA,NA,NA,NA
25960,72,Colorectal Cancer,Colon Adenocarcinoma,68,COAD,55.55,1:DECEASED,1,Metastatic,Matched,2.3,Colon,Female,COLO,Liver,Liver,26,NA,NA,NA,NA,No,NA,62,NA,NA,NA,NA,NA,NA,NA
25961,64,Hepatobiliary Cancer,Intrahepatic Cholangiocarcinoma,27,IHCH,15.41,1:DECEASED,1,Metastatic,Matched,0.9333333333,Bile Duct,Female,CHOL,Liver,Liver,16,NA,NA,NA,NA,No,NA,50,NA,NA,NA,NA,NA,NA,NA
25962,62,Breast Cancer,Breast Invasive Ductal Carcinoma,19,IDC,33.84,1:DECEASED,1,Metastatic,Matched,0.6333333333,Breast,Female,BRCA,Liver,Liver,13,NA,NA,NA,NA,No,NA,83,NA,NA,NA,NA,NA,NA,NA
25964,71,Cancer of Unknown Primary,Cancer of Unknown Primary,68,CUP,4.01,1:DECEASED,1,Unknown,Matched,2.3,NA,Male,MISC,Spine,Spine,37,NA,NA,NA,NA,No,NA,32,NA,NA,NA,NA,NA,NA,NA
25965,49,Anal Cancer,Anal Squamous Cell Carcinoma,26,ANSC,11.43,1:DECEASED,1,Metastatic,Matched,0.9,Anus,Male,COLO,Liver,Liver,40,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
25966,69,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,145,LUAD,52.92,1:DECEASED,1,Metastatic,Matched,4.9,Lung,Female,LUNG,Lymphatic System,Lymph Node,2,Nivolumab,Physician assessed SD,Durable clinical benefit,Mut per Mb < 10,Yes,PD-1,35,0,0.170690559,0,0.061959257,0.031031612,0,0.010527947
25976,57,Endometrial Cancer,Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor,NA,UCS,12.06,1:DECEASED,1,Local Recurrence,Matched,0,Uterus,Female,UCEC,Reproductive System,Vaginal Vault,0,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
25977,46,Soft Tissue Sarcoma,Leiomyosarcoma,25,LMS,35.87,1:DECEASED,1,Metastatic,Matched,0.8333333333,NA,Male,SARC,Soft Tissue,Neck mass,28,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
25979,79,Pancreatic Cancer,Pancreatic Adenocarcinoma,1,PAAD,5.91,1:DECEASED,1,Local Recurrence,Matched,0.03333333333,Pancreas,Male,PANC,Pancreas,Pancreas,0,NA,NA,NA,NA,No,NA,24,NA,NA,NA,NA,NA,NA,NA
25980,59,Breast Cancer,Breast Invasive Ductal Carcinoma,119,IDC,49.64,0:LIVING,1,Metastatic,Matched,4.033333333,Breast,Female,BRCA,Chest Wall,Sternal,62,Pembrolizumab,Partial response,Durable clinical benefit,Mut per Mb < 10,Yes,PD-1,62,0.016702952,0.174267356,0,0.142926214,0.062440564,0,0.019157007
25981,77,Colorectal Cancer,Colon Adenocarcinoma,93,COAD,19.02,1:DECEASED,1,Metastatic,Matched,3.133333333,Colon,Male,COLO,Liver,Liver,22,NA,NA,NA,NA,No,NA,64,NA,NA,NA,NA,NA,NA,NA
25982,58,Breast Cancer,Breast Invasive Ductal Carcinoma,12,IDC,7.26,1:DECEASED,1,Metastatic,Matched,0.4,Breast,Female,BRCA,Liver,Liver,19,NA,NA,NA,NA,No,NA,73,NA,NA,NA,NA,NA,NA,NA
25984,57,Breast Cancer,Invasive Breast Carcinoma,82,BRCA,16.33,1:DECEASED,1,Metastatic,Matched,2.766666667,Breast,Female,BRCA,Liver,Liver,64,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
25988,59,Ovarian Cancer,High-Grade Serous Ovarian Cancer,8,HGSOC,54.04,1:DECEASED,1,Metastatic,Matched,0.2666666667,Ovary,Female,OV,Lymphatic System,Lymph Node,58,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
25989,55,Sex Cord Stromal Tumor,Granulosa Cell Tumor,20,GRCT,38.73,1:DECEASED,1,Metastatic,Matched,0.6666666667,Ovary,Female,MISC,Liver,Liver,5,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
25990,58,Breast Cancer,Breast Invasive Ductal Carcinoma,97,IDC,41.85,0:LIVING,1,Metastatic,Matched,3.266666667,Breast,Female,BRCA,Liver,Liver,21,NA,NA,NA,NA,No,NA,84,NA,NA,NA,NA,NA,NA,NA
25991,19,Glioma,Glioblastoma Multiforme,23,GBM,44.58,1:DECEASED,1,Local Recurrence,Matched,0.7666666667,Brain,Female,CNS-PNS,Brain,Brain,14,NA,NA,NA,NA,No,NA,72,NA,NA,NA,NA,NA,NA,NA
26016,59,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,35,LUAD,19.35,1:DECEASED,1,Metastatic,Matched,1.2,Lung,Female,LUNG,Skin,Scalp,24,Nivolumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,41,0.01865245,0.366088215,0,0.183649854,0.112492702,0,0.100910807
26017,38,Thyroid Cancer,Medullary Thyroid Cancer,24,THME,100.76,1:DECEASED,1,Metastatic,Matched,0.8,Thyroid,Female,THCA,Liver,Liver,0,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
26051,77,Colorectal Cancer,Colon Adenocarcinoma,61,COAD,4.53,1:DECEASED,1,Metastatic,Matched,2.033333333,Colon,Male,COLO,Liver,Liver,40,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
26052,59,Endometrial Cancer,Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor,16,UCS,18.99,1:DECEASED,1,Metastatic,Matched,0.5333333333,Uterus,Female,UCEC,Reproductive System,Omentum,27,NA,NA,NA,NA,No,NA,37,NA,NA,NA,NA,NA,NA,NA
26054,65,Breast Cancer,Breast Invasive Lobular Carcinoma,23,ILC,26.15,1:DECEASED,1,Metastatic,Matched,0.7666666667,Breast,Female,BRCA,Chest Wall,Chest wall,20,NA,NA,NA,NA,No,NA,89,NA,NA,NA,NA,NA,NA,NA
26066,57,Uterine Sarcoma,Uterine Leiomyosarcoma,22,ULMS,34.86,1:DECEASED,1,Metastatic,Matched,0.7333333333,Uterus,Female,SARC,Soft Tissue,Pelvis,28,NA,NA,NA,NA,No,NA,89,NA,NA,NA,NA,NA,NA,NA
26123,48,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,185,LUSC,23.29,1:DECEASED,1,Local Recurrence,Matched,6.2,Lung,Male,LUNG,Respiratory System,Bronchus,41,Nivolumab,Not evaluable,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,97,0.000536313,0.001397049,0,0.012839439,0.005458399,0,0.004909248
26124,65,Colorectal Cancer,Colon Adenocarcinoma,59,COAD,46.32,1:DECEASED,1,Metastatic,Matched,2.033333333,Colon,Male,COLO,Liver,Liver,9,NA,NA,NA,NA,No,NA,85,NA,NA,NA,NA,NA,NA,NA
26125,49,Esophagogastric Cancer,Stomach Adenocarcinoma,41,STAD,30.55,1:DECEASED,1,Metastatic,Matched,1.4,Stomach,Female,STAD,Reproductive System,Ovary,33,"Pembrolizumab, Nivolumab",Physician assessed SD,Durable clinical benefit,Mut per Mb < 10,Yes,PD-1,45,0,0.067506327,0,0.014501139,0,0,0.01147229
26239,67,Colorectal Cancer,Colon Adenocarcinoma,58,COAD,97.67,0:LIVING,1,Metastatic,Matched,1.966666667,Colon,Female,COLO,Liver,Liver,2,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
26266,55,Breast Cancer,Breast Invasive Mixed Mucinous Carcinoma,54,IMMC,67.12,1:DECEASED,1,Metastatic,Matched,1.8,Breast,Female,BRCA,Breast,Breast,16,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
26376,46,Breast Cancer,Breast Invasive Ductal Carcinoma,89,IDC,20.73,1:DECEASED,1,Metastatic,Matched,2.966666667,Breast,Female,BRCA,Liver,Liver,21,Atezolizumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,42,0.026566729,0.281091335,0,0.052469146,0.007161069,0.010156572,0.004478547
26409,67,Non-Small Cell Lung Cancer,Large Cell Neuroendocrine Carcinoma,18,LUNE,20.66,1:DECEASED,1,Metastatic,Matched,0.6,Lung,Male,LUNG,Liver,Liver,21,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
26416,24,Soft Tissue Sarcoma,Clear Cell Sarcoma,13,CCS,4.93,1:DECEASED,1,Metastatic,Matched,0.4,NA,Male,SARC,Lymphatic System,Lymph Node,22,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
26465,60,Melanoma,Uveal Melanoma,15,UM,16.39,1:DECEASED,1,Metastatic,Matched,0.5,Eye,Male,UVM,Liver,Liver,18,NA,NA,NA,NA,No,NA,67,NA,NA,NA,NA,NA,NA,NA
26825,27,Ovarian Cancer,Low-Grade Serous Ovarian Cancer,7,LGSOC,63.4,0:LIVING,1,Metastatic,Matched,0.2333333333,Ovary,Female,OV,Abdomen,Abdominal Wall,14,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
26850,45,Breast Cancer,Breast Invasive Ductal Carcinoma,84,IDC,41.16,0:LIVING,1,Metastatic,Matched,2.866666667,Breast,Female,BRCA,Liver,Liver,30,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
26851,66,Colorectal Cancer,Colon Adenocarcinoma,122,COAD,76.05,1:DECEASED,1,Metastatic,Matched,4.066666667,Colon,Male,COLO,Liver,Liver,33,NA,NA,NA,NA,No,NA,59,NA,NA,NA,NA,NA,NA,NA
26852,33,Renal Cell Carcinoma,Renal Cell Carcinoma,3,RCC,38.3,0:LIVING,1,Metastatic,Matched,0.1,Kidney,Male,KDNY,Bone,Pelvic Mass,29,NA,NA,NA,NA,No,NA,53,NA,NA,NA,NA,NA,NA,NA
27025,49,Soft Tissue Sarcoma,Dedifferentiated Liposarcoma,22,DDLS,102.1,0:LIVING,1,Local Recurrence,Matched,0.7333333333,NA,Male,SARC,Abdomen,Perirenal space,18,Atezolizumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,52,0,0.357639858,0,0.380473048,0.065398201,0,0.137458926
27026,62,Endometrial Cancer,Uterine Endometrioid Carcinoma,43,UEC,24.31,1:DECEASED,1,Local Recurrence,Matched,1.5,Uterus,Female,UCEC,Reproductive System,Vaginal Vault,5,NA,NA,NA,NA,No,NA,52,NA,NA,NA,NA,NA,NA,NA
27028,63,Soft Tissue Sarcoma,Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma,48,MFH,33.48,1:DECEASED,1,Metastatic,Matched,1.6,NA,Male,SARC,Soft Tissue,Buttock,31,NA,NA,NA,NA,No,NA,50,NA,NA,NA,NA,NA,NA,NA
27034,46,Breast Cancer,Breast Invasive Ductal Carcinoma,54,IDC,40.87,0:LIVING,1,Metastatic,Matched,1.766666667,Breast,Female,BRCA,Chest Wall,Sternal mass,63,NA,NA,NA,NA,No,NA,66,NA,NA,NA,NA,NA,NA,NA
27036,41,CNS Cancer,Myxopapillary Ependymoma,4,MPE,152.6,0:LIVING,1,Local Recurrence,Matched,0.1333333333,NA,Male,CNS-PNS,Spine,Spine,0,NA,NA,NA,NA,No,NA,30,NA,NA,NA,NA,NA,NA,NA
27037,40,Breast Cancer,Breast Invasive Ductal Carcinoma,62,IDC,12.29,1:DECEASED,1,Metastatic,Matched,2.066666667,Breast,Female,BRCA,Chest Wall,Chest wall,51,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
27078,67,Pancreatic Cancer,Pancreatic Adenocarcinoma,36,PAAD,38.17,0:LIVING,1,Metastatic,Matched,1.233333333,Pancreas,Male,PANC,Liver,Liver,38,NA,NA,NA,NA,No,NA,49,NA,NA,NA,NA,NA,NA,NA
27090,39,Breast Cancer,Breast Invasive Ductal Carcinoma,41,IDC,65.7,0:LIVING,1,Metastatic,Matched,1.466666667,Breast,Female,BRCA,Liver,Liver,5,NA,NA,NA,NA,No,NA,39,NA,NA,NA,NA,NA,NA,NA
27177,46,Renal Cell Carcinoma,Collecting Duct Renal Cell Carcinoma,35,CDRCC,8.44,1:DECEASED,1,Metastatic,Matched,1.166666667,Kidney,Male,KDNY,Liver,Liver,34,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
27178,57,Esophagogastric Cancer,Adenocarcinoma of the Gastroesophageal Junction,86,GEJ,5.49,1:DECEASED,1,Metastatic,Matched,2.9,Gastroesophageal Junction,Male,ESCA,Liver,Liver,31,NA,NA,NA,NA,No,NA,72,NA,NA,NA,NA,NA,NA,NA
27216,64,Breast Cancer,Breast Invasive Ductal Carcinoma,27,IDC,81.77,0:LIVING,1,Metastatic,Matched,0.9,Breast,Female,BRCA,Liver,Liver,15,NA,NA,NA,NA,No,NA,91,NA,NA,NA,NA,NA,NA,NA
27217,67,Colorectal Cancer,Colon Adenocarcinoma,57,COAD,26.64,1:DECEASED,1,Metastatic,Matched,1.9,Colon,Female,COLO,Liver,Liver,4,NA,NA,NA,NA,No,NA,58,NA,NA,NA,NA,NA,NA,NA
27219,69,Breast Cancer,Breast Invasive Lobular Carcinoma,34,ILC,14.45,1:DECEASED,1,Metastatic,Matched,1.133333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,22,NA,NA,NA,NA,No,NA,22,NA,NA,NA,NA,NA,NA,NA
27228,39,Ovarian Cancer,Small Cell Carcinoma of the Ovary,93,SCCO,9.76,1:DECEASED,1,Metastatic,Matched,3.133333333,Ovary,Female,OV,Lymphatic System,Lymph Node,52,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
27327,45,Breast Cancer,Breast Invasive Ductal Carcinoma,21,IDC,96.81,0:LIVING,1,Local Recurrence,Matched,0.7,Breast,Female,BRCA,Breast,Breast,33,NA,NA,NA,NA,No,NA,51,NA,NA,NA,NA,NA,NA,NA
27328,72,Breast Cancer,Breast Invasive Ductal Carcinoma,34,IDC,25.85,1:DECEASED,1,Metastatic,Matched,1.133333333,Breast,Female,BRCA,Respiratory System,Lung,36,NA,NA,NA,NA,No,NA,40,NA,NA,NA,NA,NA,NA,NA
27329,54,Breast Cancer,Breast Invasive Ductal Carcinoma,48,IDC,34.53,1:DECEASED,1,Metastatic,Matched,1.6,Breast,Female,BRCA,Liver,Liver,25,NA,NA,NA,NA,No,NA,76,NA,NA,NA,NA,NA,NA,NA
27338,52,Bone Cancer,Chordoma,23,CHDM,59.82,1:DECEASED,1,Local Recurrence,Matched,0.7333333333,NA,Male,SARC,Head & Neck,Intranasal,18,NA,NA,NA,NA,No,NA,85,NA,NA,NA,NA,NA,NA,NA
27339,34,Colorectal Cancer,Colon Adenocarcinoma,41,COAD,14.49,1:DECEASED,1,Metastatic,Matched,1.366666667,Colon,Male,COLO,Liver,Liver,29,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
27388,40,Breast Cancer,Breast Invasive Ductal Carcinoma,73,IDC,28.29,1:DECEASED,1,Metastatic,Matched,2.5,Breast,Female,BRCA,Lymphatic System,Lymph Node,64,OX40 agonist MOXR0916,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,OX40,62,0.019602656,0.067735747,0,0.0420791,0.039662542,0,0.001754834
27502,68,Breast Cancer,Breast Invasive Ductal Carcinoma,56,IDC,7.49,0:LIVING,1,Metastatic,Matched,1.933333333,Breast,Female,BRCA,Chest Wall,Chest wall,50,NA,NA,NA,NA,No,NA,58,NA,NA,NA,NA,NA,NA,NA
27503,42,Breast Cancer,Breast Invasive Ductal Carcinoma,21,IDC,38.9,0:LIVING,1,Metastatic,Matched,0.7,Breast,Female,BRCA,Lymphatic System,Lymph Node,18,NA,NA,NA,NA,No,NA,47,NA,NA,NA,NA,NA,NA,NA
27504,46,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,82,LUAD,2.56,1:DECEASED,1,Local Recurrence,Matched,2.8,Lung,Female,LUNG,Lymphatic System,Lymph Node,14,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
27519,52,Pancreatic Cancer,Pancreatic Adenocarcinoma,20,PAAD,14.59,1:DECEASED,1,Metastatic,Matched,0.6666666667,Pancreas,Male,PANC,Liver,Liver,0,NA,NA,NA,NA,No,NA,36,NA,NA,NA,NA,NA,NA,NA
27545,68,Nerve Sheath Tumor,Malignant Peripheral Nerve Sheath Tumor,53,MPNST,21.12,1:DECEASED,1,Metastatic,Matched,1.8,NA,Male,CNS-PNS,Soft Tissue,Buttock,28,NA,NA,NA,NA,No,NA,76,NA,NA,NA,NA,NA,NA,NA
27563,62,Colorectal Cancer,Colon Adenocarcinoma,41,COAD,4.34,1:DECEASED,1,Metastatic,Matched,1.4,Colon,Female,COLO,Liver,Liver,33,NA,NA,NA,NA,No,NA,60,NA,NA,NA,NA,NA,NA,NA
27647,74,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,679,LUAD,49.34,1:DECEASED,1,Local Recurrence,Matched,23.4,Lung,Male,LUNG,Respiratory System,Lung,31,NA,NA,NA,NA,No,NA,81,NA,NA,NA,NA,NA,NA,NA
27697,69,Pancreatic Cancer,Pancreatic Neuroendocrine Tumor,7,PANET,39.68,0:LIVING,1,Metastatic,Matched,0.2666666667,Pancreas,Male,PANC,Liver,Liver,22,NA,NA,NA,NA,No,NA,79,NA,NA,NA,NA,NA,NA,NA
27706,26,Adrenocortical Carcinoma,Adrenocortical Carcinoma,31,ACC,10.45,1:DECEASED,1,Local Recurrence,Matched,1.033333333,Adrenal,Female,ACC,Intestine,Pericecal Mass,29,NA,NA,NA,NA,No,NA,54,NA,NA,NA,NA,NA,NA,NA
27707,56,Ovarian Cancer,Low-Grade Serous Ovarian Cancer,5,LGSOC,16.72,1:DECEASED,1,Local Recurrence,Matched,0.1666666667,Ovary,Female,OV,Abdomen,Abdominal Mass,0,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
27721,44,Small Bowel Cancer,Duodenal Adenocarcinoma,94,DA,24.21,1:DECEASED,1,Metastatic,Matched,3.333333333,Duodenum,Male,COLO,Skin,Scalp,20,NA,NA,NA,NA,No,NA,53,NA,NA,NA,NA,NA,NA,NA
27722,58,CNS Cancer,Solitary Fibrous Tumor of the Central Nervous System,9,SFTCNS,84.69,1:DECEASED,1,Local Recurrence,Matched,0.3333333333,NA,Male,CNS-PNS,Chest Wall,Pleura,0,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
27723,67,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,28,LUAD,13.96,1:DECEASED,1,Metastatic,Matched,0.9666666667,Lung,Female,LUNG,Brain,Brain,26,NA,NA,NA,NA,No,NA,49,NA,NA,NA,NA,NA,NA,NA
27765,67,Breast Cancer,Breast Invasive Ductal Carcinoma,29,IDC,72.08,1:DECEASED,1,Metastatic,Matched,0.9666666667,Breast,Female,BRCA,Lymphatic System,Lymph Node,17,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
27784,65,Glioma,Glioblastoma Multiforme,66,GBM,9.79,1:DECEASED,1,Local Recurrence,Matched,2.2,Brain,Male,CNS-PNS,Brain,Brain,16,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
27792,60,Endometrial Cancer,Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor,31,UCS,59.36,1:DECEASED,1,Metastatic,Matched,1.066666667,Uterus,Female,UCEC,Breast,Breast,21,Monalizumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,NKG2A,62,0.008693847,0.06128373,0,0.022787649,0.057066381,0,0.00388195
27794,53,Soft Tissue Sarcoma,Dedifferentiated Liposarcoma,21,DDLS,7.39,1:DECEASED,1,Local Recurrence,Matched,0.7,NA,Male,SARC,Abdomen,Abdominal Mass,19,NA,NA,NA,NA,No,NA,75,NA,NA,NA,NA,NA,NA,NA
27795,61,Esophagogastric Cancer,Esophageal Adenocarcinoma,104,ESCA,24.51,1:DECEASED,1,Local Recurrence,Matched,3.533333333,Esophagus,Male,ESCA,Head & Neck,Esophagus,10,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
27981,26,Bone Cancer,Osteosarcoma,37,OS,37.48,1:DECEASED,1,Unknown,Matched,1.266666667,NA,Female,SARC,Spine,Spine,33,Pembrolizumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,70,0,0.208606168,0,0,0,0,0
28003,65,Non-Small Cell Lung Cancer,Atypical Lung Carcinoid,10,ALUCA,47.6,0:LIVING,1,Local Recurrence,Matched,0.3666666667,Lung,Female,LUNG,Respiratory System,Lung,7,NA,NA,NA,NA,No,NA,61,NA,NA,NA,NA,NA,NA,NA
28012,57,Ovarian Cancer,High-Grade Serous Ovarian Cancer,62,HGSOC,40.41,0:LIVING,1,Metastatic,Matched,2.1,Ovary,Female,OV,Lymphatic System,Lymph Node,54,NA,NA,NA,NA,No,NA,36,NA,NA,NA,NA,NA,NA,NA
28123,42,Salivary Gland Cancer,Adenoid Cystic Carcinoma,11,ACYC,135.18,0:LIVING,1,Metastatic,Matched,0.3666666667,Salivary Gland,Male,SECR,Respiratory System,Lung,7,"Tremelimumab, Durvalumab",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1/CTLA-4,68,0,0.254562133,0,0.077701599,0,0,0
28124,64,Appendiceal Cancer,Appendiceal Adenocarcinoma,107,APAD,19.71,1:DECEASED,1,Metastatic,Matched,3.633333333,Appendix,Male,COLO,Reproductive System,Omentum,32,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
28125,26,Esophagogastric Cancer,Adenocarcinoma of the Gastroesophageal Junction,121,GEJ,21.65,1:DECEASED,1,Metastatic,Matched,4.1,Gastroesophageal Junction,Male,ESCA,Liver,Liver,18,Pembrolizumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,37,0.021401519,0.114154165,0,0.061345769,0.037924342,0,0.011910131
28126,57,Breast Cancer,Breast Mixed Ductal and Lobular Carcinoma,152,MDLC,33.71,1:DECEASED,1,Metastatic,Matched,5.1,Breast,Female,BRCA,Lymphatic System,Lymph Node,37,NA,NA,NA,NA,No,NA,81,NA,NA,NA,NA,NA,NA,NA
28130,37,Pancreatic Cancer,Pancreatic Neuroendocrine Tumor,26,PANET,8.34,1:DECEASED,1,Metastatic,Matched,0.9,Pancreas,Male,PANC,Liver,Liver,13,NA,NA,NA,NA,No,NA,79,NA,NA,NA,NA,NA,NA,NA
28131,36,Breast Cancer,Breast Invasive Ductal Carcinoma,57,IDC,10.15,1:DECEASED,1,Local Recurrence,Matched,1.933333333,Breast,Female,BRCA,Breast,Breast,55,NA,NA,NA,NA,No,NA,76,NA,NA,NA,NA,NA,NA,NA
28132,72,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,20,LUSC,27.37,1:DECEASED,1,Local Recurrence,Matched,0.6666666667,Lung,Male,LUNG,Respiratory System,Lung,13,Nivolumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,25,0.143405875,0.232257126,0,0.545646344,0.149556113,0,0.215007551
28170,56,Salivary Gland Cancer,Salivary Duct Carcinoma,58,SDCA,13.93,1:DECEASED,1,Metastatic,Matched,1.966666667,Parotid Gland,Male,SECR,Lymphatic System,Lymph Node,26,NA,NA,NA,NA,No,NA,59,NA,NA,NA,NA,NA,NA,NA
28171,71,Mesothelioma,Pleural Mesothelioma,32,PLMESO,26.08,1:DECEASED,1,Local Recurrence,Matched,1.133333333,Pleura,Male,LUNG,Respiratory System,Lung,8,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
28178,42,Breast Cancer,Breast Invasive Ductal Carcinoma,46,IDC,18.99,1:DECEASED,1,Metastatic,Matched,1.533333333,Breast,Female,BRCA,Abdomen,Abdominal Wall,24,Pembrolizumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,67,0.026636973,0.0990464,0,0.076171217,0.05707724,0,0
28212,51,Pancreatic Cancer,Pancreatic Adenocarcinoma,35,PAAD,6.21,1:DECEASED,1,Metastatic,Matched,1.166666667,Pancreas,Female,PANC,Liver,Liver,28,Durvalumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1,52,0,0.118614364,0,0.023879014,0.001355445,0,0.044113233
28224,49,Melanoma,Melanoma,410,MEL,38.04,0:LIVING,1,Metastatic,Matched,14.06666667,Skin,Male,SKCM,Lymphatic System,Lymph Node,14,Nivolumab,Physician assessed PR,Durable clinical benefit,Mut per Mb >= 10,Yes,PD-1,90,0.00017627,0.020800116,0,0.011487718,0.024019464,0,0
28225,67,Breast Cancer,Breast Invasive Ductal Carcinoma,23,IDC,64.39,0:LIVING,1,Local Recurrence,Matched,0.7666666667,Breast,Female,BRCA,Breast,Breast,13,NA,NA,NA,NA,No,NA,71,NA,NA,NA,NA,NA,NA,NA
28226,70,Colorectal Cancer,Colon Adenocarcinoma,101,COAD,9.66,0:LIVING,1,Metastatic,Matched,3.4,Colon,Male,COLO,Liver,Liver,32,NA,NA,NA,NA,No,NA,52,NA,NA,NA,NA,NA,NA,NA
28278,60,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,375,LUAD,57.79,1:DECEASED,1,Local Recurrence,Matched,12.83333333,Lung,Female,LUNG,Respiratory System,Lung,26,Nivolumab,Physician assessed SD,Durable clinical benefit,Mut per Mb >= 10,Yes,PD-1,40,0,0.153434937,0,0.001723066,0.038163265,0,0
28312,60,Uterine Sarcoma,Uterine Leiomyosarcoma,21,ULMS,41.06,0:LIVING,1,Metastatic,Matched,0.7,Uterus,Female,SARC,Soft Tissue,Pelvis,0,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
28324,68,Colorectal Cancer,Colon Adenocarcinoma,118,COAD,14.45,1:DECEASED,1,Metastatic,Matched,4,Colon,Male,COLO,Liver,Liver,22,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
28325,57,Breast Cancer,Breast Invasive Lobular Carcinoma,32,ILC,62.16,1:DECEASED,1,Metastatic,Matched,1.066666667,Breast,Female,BRCA,Liver,Liver,20,NA,NA,NA,NA,No,NA,62,NA,NA,NA,NA,NA,NA,NA
28326,80,Non-Small Cell Lung Cancer,Poorly Differentiated Non-Small Cell Lung Cancer,137,NSCLCPD,1.41,1:DECEASED,1,Local Recurrence,Matched,4.666666667,Lung,Male,LUNG,Lymphatic System,Lymph Node,35,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
28374,57,Colorectal Cancer,Mucinous Adenocarcinoma of the Colon and Rectum,57,MACR,4.8,1:DECEASED,1,Metastatic,Matched,1.966666667,Rectum,Female,COLO,Soft Tissue,Flank Mass,12,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
28380,62,Pancreatic Cancer,Pancreatic Adenocarcinoma,21,PAAD,16.46,1:DECEASED,1,Metastatic,Matched,0.7333333333,Pancreas,Male,PANC,Liver,Liver,2,NA,NA,NA,NA,No,NA,33,NA,NA,NA,NA,NA,NA,NA
28381,61,Breast Cancer,Invasive Breast Carcinoma,24,BRCA,36.37,0:LIVING,1,Local Recurrence,Matched,0.8,Breast,Female,BRCA,Breast,Breast,9,NA,NA,NA,NA,No,NA,52,NA,NA,NA,NA,NA,NA,NA
28382,60,Breast Cancer,Breast Ductal Carcinoma In Situ,20,DCIS,52.63,1:DECEASED,1,Metastatic,Matched,0.6666666667,Breast,Female,BRCA,Liver,Liver,26,NA,NA,NA,NA,No,NA,64,NA,NA,NA,NA,NA,NA,NA
28384,35,CNS Cancer,Anaplastic Ependymoma,20,APE,96.98,0:LIVING,1,Local Recurrence,Matched,0.7,NA,Female,CNS-PNS,Brain,Brain,9,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
28391,71,Breast Cancer,Breast Invasive Ductal Carcinoma,46,IDC,21.62,1:DECEASED,1,Metastatic,Matched,1.533333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,29,NA,NA,NA,NA,No,NA,64,NA,NA,NA,NA,NA,NA,NA
28392,59,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,29,LUAD,53.78,0:LIVING,1,Local Recurrence,Matched,1,Lung,Female,LUNG,Respiratory System,Lung,10,NA,NA,NA,NA,No,NA,47,NA,NA,NA,NA,NA,NA,NA
28421,72,Mesothelioma,Pleural Mesothelioma,25,PLMESO,18.46,0:LIVING,1,Metastatic,Matched,0.8333333333,Pleura,Male,LUNG,Chest Wall,Pleura,3,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
28422,42,Breast Cancer,Breast Invasive Ductal Carcinoma,53,IDC,6.21,1:DECEASED,1,Metastatic,Matched,1.8,Breast,Female,BRCA,Lymphatic System,Lymph Node,36,NA,NA,NA,NA,No,NA,44,NA,NA,NA,NA,NA,NA,NA
28427,82,Pancreatic Cancer,Pancreatic Adenocarcinoma,29,PAAD,7.23,1:DECEASED,1,Local Recurrence,Matched,0.9666666667,Pancreas,Female,PANC,Pancreas,Pancreas,3,NA,NA,NA,NA,No,NA,43,NA,NA,NA,NA,NA,NA,NA
28428,49,Colorectal Cancer,Colon Adenocarcinoma,41,COAD,24.87,0:LIVING,1,Metastatic,Matched,1.366666667,Colon,Female,COLO,Liver,Liver,31,NA,NA,NA,NA,No,NA,26,NA,NA,NA,NA,NA,NA,NA
28430,55,"Skin Cancer, Non-Melanoma",Sweat Gland Carcinoma/Apocrine Eccrine Carcinoma,18,AECA,15.34,1:DECEASED,1,Local Recurrence,Matched,0.6,Breast,Female,SECR,Lymphatic System,Lymph Node,13,Pembrolizumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,26,0,0.120830944,0,0.081122124,0.037636216,0,0.040532939
28494,66,Colorectal Cancer,Colon Adenocarcinoma,123,COAD,22.21,1:DECEASED,1,Metastatic,Matched,4.3,Colon,Female,COLO,Liver,Liver,17,NA,NA,NA,NA,No,NA,47,NA,NA,NA,NA,NA,NA,NA
28495,65,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,NA,NSCLC,35.45,1:DECEASED,1,Local Recurrence,Matched,0,Lung,Female,LUNG,Lymphatic System,Lymph Node,0,Nivolumab,Physician assessed PR,Durable clinical benefit,Mut per Mb < 10,Yes,PD-1,23,0.229876961,0.540513642,0,0.267481149,0,0.050945246,0
28496,45,Colorectal Cancer,Colon Adenocarcinoma,62,COAD,16.23,0:LIVING,1,Metastatic,Matched,2.066666667,Colon,Female,COLO,Liver,Liver,14,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
28497,49,Colorectal Cancer,Colon Adenocarcinoma,61,COAD,22.86,1:DECEASED,1,Local Recurrence,Matched,2.033333333,Colon,Female,COLO,Intestine,Colon,32,NA,NA,NA,NA,No,NA,51,NA,NA,NA,NA,NA,NA,NA
28590,72,Mature B-Cell Neoplasms,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,26,CLLSLL,30.81,0:LIVING,1,Local Recurrence,Matched,0.9,Blood,Male,LYMP,Blood,Peripheral Blood,8,NA,NA,NA,NA,No,NA,99,NA,NA,NA,NA,NA,NA,NA
28638,55,Ovarian Cancer,Clear Cell Ovarian Cancer,54,CCOV,5.81,0:LIVING,1,Metastatic,Matched,1.866666667,Ovary,Female,OV,Abdomen,Abdominal Mass,19,NA,NA,NA,NA,No,NA,47,NA,NA,NA,NA,NA,NA,NA
28665,51,Breast Cancer,Breast Invasive Ductal Carcinoma,28,IDC,38.9,1:DECEASED,1,Metastatic,Matched,0.9333333333,Breast,Female,BRCA,Liver,Liver,9,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
28666,50,Colorectal Cancer,Colon Adenocarcinoma,51,COAD,29.83,1:DECEASED,1,Metastatic,Matched,1.733333333,Colon,Male,COLO,Liver,Liver,28,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
28667,63,Ovarian Cancer,Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor,33,OCS,20.96,1:DECEASED,1,Metastatic,Matched,1.1,Ovary,Female,OV,Soft Tissue,Pelvic Mass,19,NA,NA,NA,NA,No,NA,71,NA,NA,NA,NA,NA,NA,NA
28668,70,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,208,NSCLC,15.08,1:DECEASED,1,Metastatic,Matched,7.1,Lung,Male,LUNG,Bone,Rib,28,Nivolumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,45,0.044059692,0.191941555,0,0.049168552,0.03305595,0,0.008985463
29146,59,Colorectal Cancer,Colon Adenocarcinoma,920,COAD,10.68,1:DECEASED,1,Metastatic,Matched,31.13333333,Colon,Male,COLO,Liver,Liver,18,Pembrolizumab,Not evaluable,No durable clinical benefit,Mut per Mb >= 10,Yes,PD-1,69,0,0.115022604,0,0.02822767,0.048697646,0,0.033038922
29147,70,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,719,LUAD,190.14,1:DECEASED,1,Metastatic,Matched,24.5,Lung,Female,LUNG,Liver,Liver,40,NA,NA,NA,NA,No,NA,67,NA,NA,NA,NA,NA,NA,NA
29148,36,Soft Tissue Sarcoma,Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma,5,MFH,40.57,1:DECEASED,1,Local Recurrence,Matched,0.1666666667,NA,Female,SARC,Head & Neck,Masticular Space,1,NA,NA,NA,NA,No,NA,29,NA,NA,NA,NA,NA,NA,NA
29149,39,Breast Cancer,Breast Invasive Ductal Carcinoma,33,IDC,2.27,1:DECEASED,1,Local Recurrence,Matched,1.1,Breast,Female,BRCA,Breast,Breast,43,NA,NA,NA,NA,No,NA,51,NA,NA,NA,NA,NA,NA,NA
29759,69,Breast Cancer,Breast Invasive Lobular Carcinoma,118,ILC,35.64,1:DECEASED,1,Metastatic,Matched,4,Breast,Female,BRCA,Liver,Liver,28,NA,NA,NA,NA,No,NA,69,NA,NA,NA,NA,NA,NA,NA
29761,31,Breast Cancer,Breast Invasive Ductal Carcinoma,17,IDC,33.9,0:LIVING,1,Local Recurrence,Matched,0.5666666667,Breast,Female,BRCA,Breast,Breast,20,NA,NA,NA,NA,No,NA,54,NA,NA,NA,NA,NA,NA,NA
29766,52,Appendiceal Cancer,Appendiceal Adenocarcinoma,201,APAD,8.41,1:DECEASED,1,Metastatic,Matched,6.9,Appendix,Female,COLO,Liver,Liver,23,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
29999,40,Colorectal Cancer,Colon Adenocarcinoma,76,COAD,28.91,1:DECEASED,1,Metastatic,Matched,2.5,Colon,Female,COLO,Liver,Liver,27,NA,NA,NA,NA,No,NA,60,NA,NA,NA,NA,NA,NA,NA
30000,59,Small Cell Lung Cancer,Small Cell Lung Cancer,46,SCLC,28.94,0:LIVING,1,Metastatic,Matched,1.533333333,Lung,Female,LUNG,Liver,Liver,0,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
30009,51,Thymic Tumor,Thymic Carcinoma,19,THYC,6.08,0:LIVING,1,Local Recurrence,Matched,0.6666666667,Thymus,Female,THYM,Chest Wall,Pleura,7,NA,NA,NA,NA,No,NA,51,NA,NA,NA,NA,NA,NA,NA
30011,70,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,124,LUSC,5.75,1:DECEASED,1,Local Recurrence,Matched,4.3,Lung,Male,LUNG,Respiratory System,Bronchus,29,NA,NA,NA,NA,No,NA,49,NA,NA,NA,NA,NA,NA,NA
30032,79,Prostate Cancer,Prostate Adenocarcinoma,37,PRAD,34.2,0:LIVING,1,Metastatic,Matched,1.266666667,Prostate,Male,PRAD,Bone,Sacrum,14,NA,NA,NA,NA,No,NA,50,NA,NA,NA,NA,NA,NA,NA
30078,28,Bone Cancer,Ewing Sarcoma,21,ES,29.24,1:DECEASED,1,Unknown,Matched,0.7,NA,Female,SARC,Reproductive System,Vaginal Wall,8,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
30080,34,Colorectal Cancer,Colon Adenocarcinoma,96,COAD,9.95,1:DECEASED,1,Metastatic,Matched,3.266666667,Colon,Female,COLO,Lymphatic System,Lymph Node,56,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
30081,44,Thymic Tumor,Thymoma,15,THYM,183.57,0:LIVING,1,Metastatic,Matched,0.5,Thymus,Female,THYM,Lymphatic System,Lymph Node,2,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
30082,62,Salivary Gland Cancer,Adenoid Cystic Carcinoma,12,ACYC,11.17,1:DECEASED,1,Metastatic,Matched,0.4333333333,unknown,Male,SECR,Liver,Liver,6,NA,NA,NA,NA,No,NA,95,NA,NA,NA,NA,NA,NA,NA
30083,74,Ovarian Cancer,High-Grade Serous Ovarian Cancer,48,HGSOC,38.57,0:LIVING,1,Metastatic,Matched,1.666666667,Ovary,Female,OV,Lymphatic System,Lymph Node,23,NA,NA,NA,NA,No,NA,60,NA,NA,NA,NA,NA,NA,NA
30159,69,Colorectal Cancer,Colon Adenocarcinoma,45,COAD,25.1,1:DECEASED,1,Metastatic,Matched,1.5,Colon,Male,COLO,Liver,Liver,2,NA,NA,NA,NA,No,NA,28,NA,NA,NA,NA,NA,NA,NA
30220,24,Bone Cancer,Chondroblastic Osteosarcoma,68,CHOS,6.77,1:DECEASED,1,Metastatic,Matched,2.3,NA,Male,SARC,Soft Tissue,Thigh Mass,27,NA,NA,NA,NA,No,NA,64,NA,NA,NA,NA,NA,NA,NA
30221,54,Breast Cancer,Carcinoma with Chondroid Metaplasia,172,CCHM,29.8,1:DECEASED,1,Metastatic,Matched,5.766666667,NA,Female,MISC,Lymphatic System,Lymph Node,64,Pembrolizumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,63,0,0.158512524,0,0.186254729,0.147327938,0.025437075,0.012678043
30222,60,Esophagogastric Cancer,Adenocarcinoma of the Gastroesophageal Junction,61,GEJ,8.51,1:DECEASED,1,Metastatic,Matched,2.033333333,Gastroesophageal Junction,Male,ESCA,Liver,Liver,55,NA,NA,NA,NA,No,NA,63,NA,NA,NA,NA,NA,NA,NA
30248,48,Breast Cancer,Breast Invasive Ductal Carcinoma,42,IDC,58.74,1:DECEASED,1,Metastatic,Matched,1.4,Breast,Female,BRCA,Chest Wall,Chest wall,22,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
30250,56,Head and Neck Cancer,Oropharynx Squamous Cell Carcinoma,18,OPHSC,10.64,1:DECEASED,1,Metastatic,Matched,0.6,Oropharynx,Male,HNSC,Respiratory System,Lung,18,NA,NA,NA,NA,No,NA,66,NA,NA,NA,NA,NA,NA,NA
30251,53,Colorectal Cancer,Colon Adenocarcinoma,79,COAD,16.66,1:DECEASED,1,Metastatic,Matched,2.633333333,Colon,Male,COLO,Liver,Liver,27,NA,NA,NA,NA,No,NA,72,NA,NA,NA,NA,NA,NA,NA
30252,41,Breast Cancer,Breast Invasive Ductal Carcinoma,38,IDC,95.27,1:DECEASED,1,Metastatic,Matched,1.3,Breast,Female,BRCA,Liver,Liver,50,NA,NA,NA,NA,No,NA,58,NA,NA,NA,NA,NA,NA,NA
30253,39,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,6,LUAD,32.79,0:LIVING,1,Local Recurrence,Matched,0.2,Lung,Female,LUNG,Respiratory System,Lung,19,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
30254,22,CNS Cancer,Anaplastic Ependymoma,13,APE,22.34,1:DECEASED,1,Local Recurrence,Matched,0.4333333333,NA,Male,CNS-PNS,Brain,Brain,18,NA,NA,NA,NA,No,NA,67,NA,NA,NA,NA,NA,NA,NA
30265,68,Pancreatic Cancer,Pancreatic Adenocarcinoma,50,PAAD,38.83,1:DECEASED,1,Metastatic,Matched,1.733333333,Pancreas,Male,PANC,Abdomen,Abdominal Wall,1,NA,NA,NA,NA,No,NA,44,NA,NA,NA,NA,NA,NA,NA
30309,82,Colorectal Cancer,Colon Adenocarcinoma,48,COAD,40.57,1:DECEASED,1,Metastatic,Matched,1.633333333,Colon,Female,COLO,Reproductive System,Omentum,1,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
30310,51,Adrenocortical Carcinoma,Adrenocortical Carcinoma,33,ACC,33.84,0:LIVING,1,Metastatic,Matched,1.1,Adrenal,Female,ACC,Respiratory System,Lung,32,NA,NA,NA,NA,No,NA,84,NA,NA,NA,NA,NA,NA,NA
30311,64,Renal Cell Carcinoma,Renal Angiomyolipoma,12,RAML,48.46,0:LIVING,1,Metastatic,Matched,0.4,Kidney,Male,KDNY,Abdomen,Mesenteric Mass,17,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
30313,65,Breast Cancer,Breast Invasive Ductal Carcinoma,67,IDC,20.34,1:DECEASED,1,Metastatic,Matched,2.266666667,Breast,Female,BRCA,Respiratory System,Lung,38,Atezolizumab,Stable disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,30,0.00533568,0.191708753,0,0.218389353,0.138274573,0,0.012777103
30321,64,Colorectal Cancer,Colon Adenocarcinoma,66,COAD,27.37,1:DECEASED,1,Metastatic,Matched,2.233333333,Colon,Female,COLO,Liver,Liver,22,NA,NA,NA,NA,No,NA,61,NA,NA,NA,NA,NA,NA,NA
30425,73,Breast Cancer,Breast Invasive Ductal Carcinoma,70,IDC,31.54,1:DECEASED,1,Metastatic,Matched,2.366666667,Breast,Female,BRCA,Liver,Liver,37,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
30426,45,Endometrial Cancer,Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor,33,UCS,21.65,1:DECEASED,1,Metastatic,Matched,1.1,Uterus,Female,UCEC,Respiratory System,Lung,23,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
30431,24,Miscellaneous Neuroepithelial Tumor,Paraganglioma,9,PGNG,61.99,0:LIVING,1,Metastatic,Matched,0.3,NA,Male,CNS-PNS,Liver,Liver,18,NA,NA,NA,NA,No,NA,71,NA,NA,NA,NA,NA,NA,NA
30487,59,Breast Cancer,Breast Invasive Ductal Carcinoma,38,IDC,10.09,1:DECEASED,1,Metastatic,Matched,1.266666667,Breast,Female,BRCA,Lymphatic System,Lymph Node,23,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
30488,70,Breast Cancer,Breast Invasive Ductal Carcinoma,59,IDC,66.52,1:DECEASED,1,Metastatic,Matched,1.966666667,Breast,Female,BRCA,Lymphatic System,Lymph Node,6,NA,NA,NA,NA,No,NA,85,NA,NA,NA,NA,NA,NA,NA
30489,57,Melanoma,Melanoma,1263,MEL,45.27,1:DECEASED,1,Metastatic,Matched,43.06666667,Skin,Male,SKCM,Soft Tissue,Arm,13,NA,NA,NA,NA,No,NA,85,NA,NA,NA,NA,NA,NA,NA
30490,58,Adrenocortical Carcinoma,Adrenocortical Carcinoma,32,ACC,50.03,1:DECEASED,1,Metastatic,Matched,1.066666667,Adrenal,Female,ACC,Lymphatic System,Lymph Node,20,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
30491,65,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,LUAD,11.63,1:DECEASED,1,Local Recurrence,Matched,2.733333333,Lung,Male,LUNG,Respiratory System,Lung,36,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
30492,48,Colorectal Cancer,Colon Adenocarcinoma,82,COAD,37.39,1:DECEASED,1,Metastatic,Matched,2.833333333,Colon,Male,COLO,Liver,Liver,34,NA,NA,NA,NA,No,NA,52,NA,NA,NA,NA,NA,NA,NA
30497,76,Colorectal Cancer,Colon Adenocarcinoma,60,COAD,16.33,1:DECEASED,1,Metastatic,Matched,2.033333333,Colon,Male,COLO,Liver,Liver,24,NA,NA,NA,NA,No,NA,59,NA,NA,NA,NA,NA,NA,NA
30498,33,Pancreatic Cancer,Pancreatic Neuroendocrine Tumor,34,PANET,30.09,1:DECEASED,1,Local Recurrence,Matched,1.166666667,Pancreas,Male,PANC,Liver,Liver,5,NA,NA,NA,NA,No,NA,68,NA,NA,NA,NA,NA,NA,NA
30500,55,Hepatobiliary Cancer,Gallbladder Cancer,66,GBC,41.16,1:DECEASED,1,Metastatic,Matched,2.266666667,Bile Duct,Male,CHOL,Lymphatic System,Lymph Node,48,NA,NA,NA,NA,No,NA,27,NA,NA,NA,NA,NA,NA,NA
30504,41,Colorectal Cancer,Colon Adenocarcinoma,121,COAD,14.13,1:DECEASED,1,Metastatic,Matched,4.1,Colon,Male,COLO,Liver,Liver,31,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
30505,52,Salivary Gland Cancer,Adenoid Cystic Carcinoma,15,ACYC,29.2,0:LIVING,1,Local Recurrence,Matched,0.5333333333,Oral Cavity,Male,SECR,Head & Neck,Oral Cavity,0,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
30519,68,Breast Cancer,Breast Invasive Ductal Carcinoma,33,IDC,28.22,1:DECEASED,1,Local Recurrence,Matched,1.1,Breast,Female,BRCA,Breast,Breast,30,NA,NA,NA,NA,No,NA,40,NA,NA,NA,NA,NA,NA,NA
30606,55,Breast Cancer,Breast Invasive Ductal Carcinoma,53,IDC,52.73,0:LIVING,1,Local Recurrence,Matched,1.766666667,Breast,Female,BRCA,Breast,Breast,28,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
30607,65,Breast Cancer,Breast Invasive Ductal Carcinoma,21,IDC,36.5,1:DECEASED,1,Metastatic,Matched,0.7,Breast,Male,BRCA,Lymphatic System,Lymph Node,2,NA,NA,NA,NA,No,NA,60,NA,NA,NA,NA,NA,NA,NA
30608,56,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,37,LUAD,25.53,1:DECEASED,1,Local Recurrence,Matched,1.266666667,Lung,Male,LUNG,Chest Wall,Pleura,1,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
30609,47,Colorectal Cancer,Colon Adenocarcinoma,38,COAD,48.36,1:DECEASED,1,Metastatic,Matched,1.3,Colon,Male,COLO,Liver,Liver,40,NA,NA,NA,NA,No,NA,62,NA,NA,NA,NA,NA,NA,NA
30616,72,Salivary Gland Cancer,Myoepithelial Carcinoma,50,MYEC,92.64,1:DECEASED,1,Metastatic,Matched,1.733333333,NA,Female,SARC,Respiratory System,Lung,35,NA,NA,NA,NA,No,NA,62,NA,NA,NA,NA,NA,NA,NA
30635,62,Colorectal Cancer,Colon Adenocarcinoma,111,COAD,45.4,0:LIVING,1,Metastatic,Matched,3.8,Colon,Male,COLO,Liver,Liver,18,NA,NA,NA,NA,No,NA,57,NA,NA,NA,NA,NA,NA,NA
30784,70,Ovarian Cancer,High-Grade Serous Ovarian Cancer,50,HGSOC,48.03,0:LIVING,1,Metastatic,Matched,1.7,Ovary,Female,OV,Liver,Liver,38,NA,NA,NA,NA,No,NA,74,NA,NA,NA,NA,NA,NA,NA
30807,62,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,251,LUAD,14.29,1:DECEASED,1,Metastatic,Matched,8.7,Lung,Female,LUNG,Respiratory System,Lung,54,NA,NA,NA,NA,No,NA,44,NA,NA,NA,NA,NA,NA,NA
30809,69,Melanoma,Melanoma,2386,MEL,24.9,1:DECEASED,1,Local Recurrence,Matched,81.06666667,Skin,Male,SKCM,Skin,Skin,44,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
30810,73,Gastrointestinal Stromal Tumor,Gastrointestinal Stromal Tumor,19,GIST,101.38,0:LIVING,1,Metastatic,Matched,0.6333333333,Stomach,Male,STAD,Abdomen,Abdominal Wall,12,NA,NA,NA,NA,No,NA,95,NA,NA,NA,NA,NA,NA,NA
30811,71,Colorectal Cancer,Colon Adenocarcinoma,64,COAD,52.79,1:DECEASED,1,Metastatic,Matched,2.166666667,Colon,Male,COLO,Liver,Liver,10,NA,NA,NA,NA,No,NA,51,NA,NA,NA,NA,NA,NA,NA
30821,28,Pancreatic Cancer,Pancreatoblastoma,31,PB,10.22,1:DECEASED,1,Local Recurrence,Matched,1.033333333,Pancreas,Male,MISC,Pancreas,Pancreatic Mass,15,NA,NA,NA,NA,No,NA,64,NA,NA,NA,NA,NA,NA,NA
30822,60,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,964,LUAD,17.74,1:DECEASED,1,Local Recurrence,Matched,32.8,Lung,Female,LUNG,Lymphatic System,Lymph Node,26,Nivolumab,Not evaluable,No durable clinical benefit,Mut per Mb >= 10,Yes,PD-1,56,0.055252397,0.172473476,0,0.158486869,0.030069359,0,0.027855419
30895,62,Gastrointestinal Stromal Tumor,Gastrointestinal Stromal Tumor,16,GIST,30.81,1:DECEASED,1,Local Recurrence,Matched,0.5333333333,Stomach,Male,STAD,Abdomen,Abdominal Mass,28,NA,NA,NA,NA,No,NA,81,NA,NA,NA,NA,NA,NA,NA
30896,55,Ovarian Cancer,Low-Grade Serous Ovarian Cancer,18,LGSOC,26.28,1:DECEASED,1,Metastatic,Matched,0.6,Ovary,Female,OV,Stomach,Epigastric mass,0,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
30897,66,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,179,LUAD,27.33,1:DECEASED,1,Local Recurrence,Matched,6.033333333,Lung,Male,LUNG,Respiratory System,Lung,36,"Tremelimumab, Durvalumab",Stable disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1/CTLA-4,32,0.048198459,0.228047184,0,0.104780127,0.071813319,0,0.050005993
30902,36,Breast Cancer,Breast Invasive Ductal Carcinoma,21,IDC,29.57,1:DECEASED,1,Metastatic,Matched,0.7,Breast,Female,BRCA,Liver,Liver,40,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
31030,20,Soft Tissue Sarcoma,Alveolar Rhabdomyosarcoma,10,ARMS,3.42,1:DECEASED,1,Metastatic,Matched,0.3333333333,NA,Male,SARC,Respiratory System,Lung,2,NA,NA,NA,NA,No,NA,88,NA,NA,NA,NA,NA,NA,NA
31031,50,Breast Cancer,Breast Invasive Ductal Carcinoma,164,IDC,22.83,1:DECEASED,1,Local Recurrence,Matched,5.533333333,Breast,Female,BRCA,Breast,Breast,40,"TRASTUZUMAB, DURVALUMAB",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1/HER2,66,0.023214884,0.18807929,0,0.123731658,0.076637789,0,0.071743351
31034,51,Non-Small Cell Lung Cancer,Sarcomatoid Carcinoma of the Lung,144,SARCL,32.82,1:DECEASED,1,Local Recurrence,Matched,5,Lung,Male,LUNG,Chest Wall,Chest wall,16,Nivolumab,Physician assessed PR,Durable clinical benefit,Mut per Mb < 10,Yes,PD-1,32,0.014161643,0.134654643,0,0.075586107,0.011954397,0,0.03381922
31037,76,Esophagogastric Cancer,Adenocarcinoma of the Gastroesophageal Junction,206,GEJ,28.12,1:DECEASED,1,Metastatic,Matched,7,Gastroesophageal Junction,Male,ESCA,Lymphatic System,Lymph Node,30,NA,NA,NA,NA,No,NA,49,NA,NA,NA,NA,NA,NA,NA
31042,57,Breast Cancer,Breast Invasive Ductal Carcinoma,96,IDC,16.62,1:DECEASED,1,Metastatic,Matched,3.233333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,41,Nivolumab/anti-LAG3,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1/LAG-3,57,0,0.162241382,0,0.148659994,0.137592624,0,0.014557846
31043,53,Breast Cancer,Breast Invasive Ductal Carcinoma,30,IDC,41.16,1:DECEASED,1,Metastatic,Matched,1.033333333,Breast,Female,BRCA,Liver,Liver,43,NA,NA,NA,NA,No,NA,54,NA,NA,NA,NA,NA,NA,NA
31095,60,CNS Cancer,Meningioma,17,MNG,28.75,0:LIVING,1,Local Recurrence,Matched,0.5666666667,NA,Female,CNS-PNS,Brain,Brain,24,NA,NA,NA,NA,No,NA,78,NA,NA,NA,NA,NA,NA,NA
31183,56,Uterine Sarcoma,Uterine Leiomyosarcoma,32,ULMS,23.39,0:LIVING,1,Metastatic,Matched,1.066666667,Uterus,Female,SARC,Chest Wall,Pleura,30,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
31184,48,Melanoma,Acral Melanoma,27,ACRM,19.68,1:DECEASED,1,Metastatic,Matched,0.9,Skin,Male,SKCM,Liver,Liver,24,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
31185,43,Breast Cancer,Breast Invasive Ductal Carcinoma,15,IDC,32.62,0:LIVING,1,Metastatic,Matched,0.5,Breast,Female,BRCA,Respiratory System,Lung,45,NA,NA,NA,NA,No,NA,30,NA,NA,NA,NA,NA,NA,NA
31189,60,Breast Cancer,Carcinoma with Osseous Metaplasia,82,COM,27.07,1:DECEASED,1,Metastatic,Matched,2.733333333,NA,Female,MISC,Respiratory System,Lung,46,NA,NA,NA,NA,No,NA,48,NA,NA,NA,NA,NA,NA,NA
31190,62,Breast Cancer,Breast Invasive Ductal Carcinoma,14,IDC,24.67,1:DECEASED,1,Metastatic,Matched,0.4666666667,Breast,Female,BRCA,Lymphatic System,Lymph Node,36,NA,NA,NA,NA,No,NA,35,NA,NA,NA,NA,NA,NA,NA
31191,56,CNS Cancer,Meningioma,29,MNG,34.33,0:LIVING,1,Metastatic,Matched,1,NA,Female,CNS-PNS,Head & Neck,Orbital mass,2,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
31194,53,Gastrointestinal Stromal Tumor,Gastrointestinal Stromal Tumor,21,GIST,224.47,1:DECEASED,1,Metastatic,Matched,0.7,Stomach,Male,STAD,Abdomen,Abdomen,25,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
31369,49,Breast Cancer,Breast Mixed Ductal and Lobular Carcinoma,5,MDLC,30.09,1:DECEASED,1,Metastatic,Matched,0.1666666667,Breast,Female,BRCA,Soft Tissue,Gluteus medius,0,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
31370,57,Breast Cancer,Breast Invasive Ductal Carcinoma,68,IDC,18.1,1:DECEASED,1,Metastatic,Matched,2.3,Breast,Female,BRCA,Liver,Liver,24,NA,NA,NA,NA,No,NA,67,NA,NA,NA,NA,NA,NA,NA
31509,65,Breast Cancer,Breast Invasive Ductal Carcinoma,130,IDC,27.43,1:DECEASED,1,Metastatic,Matched,4.433333333,Breast,Female,BRCA,Liver,Liver,55,NA,NA,NA,NA,No,NA,81,NA,NA,NA,NA,NA,NA,NA
31518,53,Ovarian Cancer,Clear Cell Ovarian Cancer,68,CCOV,10.58,1:DECEASED,1,Metastatic,Matched,2.266666667,Ovary,Female,OV,Respiratory System,Diaphragm,36,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
31869,29,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,20,LUAD,29.17,0:LIVING,1,Metastatic,Matched,0.6666666667,Lung,Female,LUNG,Lymphatic System,Lymph Node,0,NA,NA,NA,NA,No,NA,28,NA,NA,NA,NA,NA,NA,NA
31870,61,Gastrointestinal Neuroendocrine Tumor,Small Bowel Well-Differentiated Neuroendocrine Tumor,24,SBWDNET,54.5,1:DECEASED,1,Metastatic,Matched,0.8333333333,Small Bowel,Male,COLO,Liver,Liver,0,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
31911,55,Pancreatic Cancer,Pancreatic Adenocarcinoma,18,PAAD,22.83,1:DECEASED,1,Metastatic,Matched,0.6,Pancreas,Female,PANC,Abdomen,Abdominal Wall,1,NA,NA,NA,NA,No,NA,28,NA,NA,NA,NA,NA,NA,NA
31923,45,Breast Cancer,Breast Invasive Ductal Carcinoma,46,IDC,27,0:LIVING,1,Metastatic,Matched,1.533333333,Breast,Female,BRCA,Liver,Liver,32,NA,NA,NA,NA,No,NA,67,NA,NA,NA,NA,NA,NA,NA
31978,51,Breast Cancer,Breast Invasive Ductal Carcinoma,28,IDC,31.04,1:DECEASED,1,Local Recurrence,Matched,0.9333333333,Breast,Female,BRCA,Breast,Breast,10,NA,NA,NA,NA,No,NA,75,NA,NA,NA,NA,NA,NA,NA
31979,42,Mature B-Cell Neoplasms,Mature B-Cell Neoplasms,211,MBN,19.22,1:DECEASED,1,Unknown,Matched,7.066666667,NA,Male,LYMP,Lymphatic System,Lymph Node,0,"Nivolumab (P1T986205),BMS-986205 (P1T986205)/IDO1 inhibitor",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1/IDO-1,40,0.424842509,0,0,1.560167146,0.22372001,0.356258856,0
31980,77,Melanoma,Head and Neck Mucosal Melanoma,90,HNMUCM,8.51,1:DECEASED,1,Metastatic,Matched,3.033333333,Sinus,Male,HNSC,Respiratory System,Lung,47,Pembrolizumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,30,0.031204495,0.402262687,0,0.571020098,0.123877397,0,0.143163327
31981,74,Non-Small Cell Lung Cancer,Large Cell Neuroendocrine Carcinoma,144,LUNE,3.68,1:DECEASED,1,Metastatic,Matched,4.9,Lung,Female,LUNG,Lymphatic System,Lymph Node,22,NA,NA,NA,NA,No,NA,40,NA,NA,NA,NA,NA,NA,NA
31982,55,Soft Tissue Sarcoma,Leiomyosarcoma,34,LMS,40.57,0:LIVING,1,Metastatic,Matched,1.166666667,NA,Male,SARC,Liver,Liver,31,NA,NA,NA,NA,No,NA,83,NA,NA,NA,NA,NA,NA,NA
32015,60,Breast Cancer,Breast Invasive Ductal Carcinoma,466,IDC,41.95,0:LIVING,1,Metastatic,Matched,15.66666667,Breast,Female,BRCA,Lymphatic System,Lymph Node,36,Pembrolizumab,Physician assessed SD,Durable clinical benefit,Mut per Mb >= 10,Yes,PD-1,74,0,0.163831964,0,0.222227214,0.030716031,0,0.06439632
32033,36,Colorectal Cancer,Colon Adenocarcinoma,129,COAD,65.05,0:LIVING,1,Metastatic,Matched,4.366666667,Colon,Female,COLO,Liver,Liver,2,NA,NA,NA,NA,No,NA,38,NA,NA,NA,NA,NA,NA,NA
32034,62,Breast Cancer,Breast Invasive Ductal Carcinoma,117,IDC,29.24,1:DECEASED,1,Metastatic,Matched,3.933333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,22,NA,NA,NA,NA,No,NA,87,NA,NA,NA,NA,NA,NA,NA
32274,55,Breast Cancer,Breast Invasive Ductal Carcinoma,99,IDC,42.64,1:DECEASED,1,Metastatic,Matched,3.366666667,Breast,Female,BRCA,Respiratory System,Lung,36,NA,NA,NA,NA,No,NA,50,NA,NA,NA,NA,NA,NA,NA
32277,38,Head and Neck Cancer,Sinonasal Adenocarcinoma,55,SNA,14.29,1:DECEASED,1,Local Recurrence,Matched,1.833333333,Sinus,Female,HNSC,Head & Neck,Intracranial tumor,32,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
32337,67,Ovarian Cancer,High-Grade Serous Ovarian Cancer,26,HGSOC,17.51,1:DECEASED,1,Metastatic,Matched,0.8666666667,Ovary,Female,OV,Soft Tissue,Rectus Muscle,25,NA,NA,NA,NA,No,NA,96,NA,NA,NA,NA,NA,NA,NA
32350,70,Ovarian Cancer,Low-Grade Serous Ovarian Cancer,29,LGSOC,124.28,1:DECEASED,1,Metastatic,Matched,0.9666666667,Ovary,Female,OV,Abdomen,Abdominal Mass,11,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
32353,35,Glioma,Pilocytic Astrocytoma,27,PAST,103.25,0:LIVING,1,Local Recurrence,Matched,0.9,NA,Female,CNS-PNS,Brain,Brain,1,NA,NA,NA,NA,No,NA,52,NA,NA,NA,NA,NA,NA,NA
32354,58,Colorectal Cancer,Colon Adenocarcinoma,82,COAD,30.03,1:DECEASED,1,Metastatic,Matched,2.8,Colon,Female,COLO,Lymphatic System,Lymph Node,18,NA,NA,NA,NA,No,NA,64,NA,NA,NA,NA,NA,NA,NA
32394,70,Mature T and NK Neoplasms,"Peripheral T-Cell lymphoma, NOS",46,PTCL,71.29,0:LIVING,1,Metastatic,Matched,1.533333333,NA,Male,LYMP,Skin,Skin,1,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
32395,73,"Skin Cancer, Non-Melanoma",Cutaneous Squamous Cell Carcinoma,1455,CSCC,16.62,1:DECEASED,1,Metastatic,Matched,49.73333333,Skin,Male,HNSC,Lymphatic System,Lymph Node,19,Pembrolizumab,Not evaluable,No durable clinical benefit,Mut per Mb >= 10,Yes,PD-1,64,0.016799619,0.033980987,0,0.149229358,0.053174328,0,0.072365344
32397,59,Breast Cancer,Breast Invasive Ductal Carcinoma,70,IDC,9.2,0:LIVING,1,Metastatic,Matched,2.366666667,Breast,Female,BRCA,Liver,Liver,15,NA,NA,NA,NA,No,NA,68,NA,NA,NA,NA,NA,NA,NA
32398,40,Breast Cancer,Breast Invasive Lobular Carcinoma,194,ILC,5.81,1:DECEASED,1,Metastatic,Matched,6.6,Breast,Female,BRCA,Liver,Liver,54,NA,NA,NA,NA,No,NA,62,NA,NA,NA,NA,NA,NA,NA
32408,69,Pancreatic Cancer,Pancreatic Adenocarcinoma,55,PAAD,15.05,1:DECEASED,1,Metastatic,Matched,1.833333333,Pancreas,Female,PANC,Liver,Liver,16,NA,NA,NA,NA,No,NA,61,NA,NA,NA,NA,NA,NA,NA
32557,40,Pancreatic Cancer,Pancreatic Adenocarcinoma,35,PAAD,12.52,1:DECEASED,1,Metastatic,Matched,1.266666667,Pancreas,Male,PANC,Liver,Liver,16,NA,NA,NA,NA,No,NA,57,NA,NA,NA,NA,NA,NA,NA
32558,46,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,27,LUAD,24.97,1:DECEASED,1,Metastatic,Matched,0.8666666667,Lung,Male,LUNG,Lymphatic System,Lymph Node,22,Nivolumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,34,0,0.23937573,0,0.121826073,0.062615032,0,0.142240351
32559,23,Soft Tissue Sarcoma,Synovial Sarcoma,21,SYNS,31.18,1:DECEASED,1,Metastatic,Matched,0.7,NA,Male,SARC,Respiratory System,Lung,0,NA,NA,NA,NA,No,NA,75,NA,NA,NA,NA,NA,NA,NA
32571,32,Breast Cancer,Breast Invasive Ductal Carcinoma,73,IDC,27.99,0:LIVING,1,Metastatic,Matched,2.5,Breast,Female,BRCA,Liver,Liver,45,NA,NA,NA,NA,No,NA,58,NA,NA,NA,NA,NA,NA,NA
32572,78,Melanoma,Cutaneous Melanoma,469,SKCM,38.14,1:DECEASED,1,Metastatic,Matched,15.93333333,Skin,Male,SKCM,Lymphatic System,Lymph Node,32,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
32573,51,Colorectal Cancer,Colon Adenocarcinoma,87,COAD,28.06,0:LIVING,1,Metastatic,Matched,2.933333333,Colon,Female,COLO,Liver,Liver,45,NA,NA,NA,NA,No,NA,36,NA,NA,NA,NA,NA,NA,NA
32654,57,Anal Cancer,Anal Squamous Cell Carcinoma,178,ANSC,30.26,1:DECEASED,1,Metastatic,Matched,5.966666667,Anus,Female,COLO,Lymphatic System,Lymph Node,29,NA,NA,NA,NA,No,NA,71,NA,NA,NA,NA,NA,NA,NA
32656,48,Pancreatic Cancer,Pancreatic Adenocarcinoma,46,PAAD,16.79,1:DECEASED,1,Metastatic,Matched,1.5,Pancreas,Male,PANC,Liver,Liver,28,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
32667,58,Melanoma,Uveal Melanoma,23,UM,10.94,1:DECEASED,1,Metastatic,Matched,0.7666666667,Eye,Female,UVM,Liver,Liver,11,Pembrolizumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,51,0.001484553,0.050206738,0,0.046016318,0.010416288,0,0.015338873
32897,52,Bone Cancer,Ewing Sarcoma,44,ES,9.3,1:DECEASED,1,Metastatic,Matched,1.5,NA,Female,SARC,Chest Wall,Chest wall,7,NA,NA,NA,NA,No,NA,81,NA,NA,NA,NA,NA,NA,NA
32959,45,Colorectal Cancer,Colon Adenocarcinoma,120,COAD,36.1,0:LIVING,1,Metastatic,Matched,4.033333333,Colon,Male,COLO,Liver,Liver,8,NA,NA,NA,NA,No,NA,58,NA,NA,NA,NA,NA,NA,NA
32960,60,Hepatobiliary Cancer,Cholangiocarcinoma,32,CHOL,2.6,1:DECEASED,1,Metastatic,Matched,1.033333333,Bile Duct,Male,CHOL,Liver,Liver,3,NA,NA,NA,NA,No,NA,40,NA,NA,NA,NA,NA,NA,NA
32971,57,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,100,LUAD,1.25,1:DECEASED,1,Metastatic,Matched,3.366666667,Lung,Male,LUNG,Liver,Liver,36,NA,NA,NA,NA,No,NA,75,NA,NA,NA,NA,NA,NA,NA
32972,51,Colorectal Cancer,Colon Adenocarcinoma,103,COAD,17.74,1:DECEASED,1,Metastatic,Matched,3.433333333,Colon,Female,COLO,Liver,Liver,19,NA,NA,NA,NA,No,NA,38,NA,NA,NA,NA,NA,NA,NA
32973,61,Breast Cancer,Breast Invasive Ductal Carcinoma,258,IDC,22.9,1:DECEASED,1,Metastatic,Matched,8.633333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,37,NA,NA,NA,NA,No,NA,45,NA,NA,NA,NA,NA,NA,NA
33033,47,Ovarian Cancer,Clear Cell Ovarian Cancer,66,CCOV,26.58,0:LIVING,1,Metastatic,Matched,2.2,Ovary,Female,OV,Lymphatic System,Lymph Node,7,NA,NA,NA,NA,No,NA,95,NA,NA,NA,NA,NA,NA,NA
33034,54,Bone Cancer,Chondrosarcoma,16,CHS,26.68,0:LIVING,1,Local Recurrence,Matched,0.5333333333,NA,Male,SARC,Respiratory System,Lung,22,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
33083,69,Melanoma,Melanoma,197,MEL,27.56,1:DECEASED,1,Metastatic,Matched,6.7,Skin,Male,SKCM,Bone,Rib,16,NA,NA,NA,NA,No,NA,58,NA,NA,NA,NA,NA,NA,NA
33127,72,Mature B-Cell Neoplasms,Follicular Lymphoma,182,FL,31.37,1:DECEASED,1,Metastatic,Matched,6.133333333,NA,Female,LYMP,Soft Tissue,Arm,8,NA,NA,NA,NA,No,NA,78,NA,NA,NA,NA,NA,NA,NA
33129,54,Pancreatic Cancer,Pancreatic Adenocarcinoma,47,PAAD,5.35,1:DECEASED,1,Metastatic,Matched,1.6,Pancreas,Male,PANC,Liver,Liver,30,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
33154,57,Breast Cancer,Breast Invasive Mixed Mucinous Carcinoma,42,IMMC,61.6,1:DECEASED,1,Metastatic,Matched,1.4,Breast,Female,BRCA,Respiratory System,Bronchus,14,NA,NA,NA,NA,No,NA,63,NA,NA,NA,NA,NA,NA,NA
33155,47,Thyroid Cancer,Follicular Thyroid Cancer,34,THFO,62.81,0:LIVING,1,Metastatic,Matched,1.1,Thyroid,Female,THCA,Lymphatic System,Lymph Node,9,NA,NA,NA,NA,No,NA,98,NA,NA,NA,NA,NA,NA,NA
33201,59,Glioma,Ganglioglioma,26,GNG,22.86,1:DECEASED,1,Local Recurrence,Matched,0.8333333333,NA,Male,CNS-PNS,Brain,Brain,14,NA,NA,NA,NA,No,NA,63,NA,NA,NA,NA,NA,NA,NA
33373,52,Cervical Cancer,Cervical Squamous Cell Carcinoma,287,CESC,53.55,1:DECEASED,1,Metastatic,Matched,9.666666667,NA,Female,CERV,Lymphatic System,Lymph Node,35,NA,NA,NA,NA,No,NA,68,NA,NA,NA,NA,NA,NA,NA
33374,62,Gastrointestinal Stromal Tumor,Gastrointestinal Stromal Tumor,44,GIST,77.96,1:DECEASED,1,Metastatic,Matched,1.466666667,Stomach,Male,STAD,Respiratory System,Lung,23,NA,NA,NA,NA,No,NA,93,NA,NA,NA,NA,NA,NA,NA
33375,56,Endometrial Cancer,Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor,69,UCS,28.48,1:DECEASED,1,Metastatic,Matched,2.433333333,Uterus,Female,UCEC,Lymphatic System,Lymph Node,26,NA,NA,NA,NA,No,NA,95,NA,NA,NA,NA,NA,NA,NA
33387,32,Esophagogastric Cancer,Stomach Adenocarcinoma,14,STAD,9.17,1:DECEASED,1,Local Recurrence,Matched,0.4666666667,Stomach,Male,STAD,Stomach,Stomach,0,NA,NA,NA,NA,No,NA,30,NA,NA,NA,NA,NA,NA,NA
33388,71,Ovarian Cancer,High-Grade Serous Ovarian Cancer,41,HGSOC,64.85,1:DECEASED,1,Metastatic,Matched,1.366666667,Ovary,Female,OV,Reproductive System,Omentum,22,NA,NA,NA,NA,No,NA,51,NA,NA,NA,NA,NA,NA,NA
33389,57,"Skin Cancer, Non-Melanoma",Basal Cell Carcinoma,342,BCC,43.27,0:LIVING,1,Metastatic,Matched,11.63333333,Skin,Female,BCC,Respiratory System,Lung,5,NA,NA,NA,NA,No,NA,89,NA,NA,NA,NA,NA,NA,NA
33480,52,Colorectal Cancer,Colon Adenocarcinoma,87,COAD,13.93,1:DECEASED,1,Metastatic,Matched,3,Colon,Female,COLO,Liver,Liver,19,"Tremelimumab, Durvalumab (GIC026)",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1/CTLA4,48,0.040974678,0.097448349,0,0.20365342,0.10355833,0,0.061340097
33532,68,Breast Cancer,Breast Invasive Ductal Carcinoma,105,IDC,29.43,0:LIVING,1,Metastatic,Matched,3.6,Breast,Female,BRCA,Chest Wall,Chest wall,29,"Nivolumab (P1T986205),BMS-986205 (P1T986205)/IDO1 inhibitor",Stable disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1/IDO-1,55,0.00613948,0,0,0.048217195,0.083061923,0,0.021010247
33546,43,Mature B-Cell Neoplasms,"Diffuse Large B-Cell Lymphoma, NOS",97,DLBCLNOS,18.69,1:DECEASED,1,Local Recurrence,Matched,3.233333333,NA,Male,LYMP,Abdomen,Rectroperitoneum,2,NA,NA,NA,NA,No,NA,95,NA,NA,NA,NA,NA,NA,NA
33740,72,Esophagogastric Cancer,Stomach Adenocarcinoma,74,STAD,18,0:LIVING,1,Metastatic,Matched,2.5,Stomach,Male,STAD,Liver,Liver,35,Nivolumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,65,0,0.167500701,0,0.09125024,0.019366046,0,0.009896559
33764,59,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,74,LUAD,34.79,0:LIVING,1,Local Recurrence,Matched,2.533333333,Lung,Male,LUNG,Respiratory System,Lung,36,NA,NA,NA,NA,No,NA,52,NA,NA,NA,NA,NA,NA,NA
33987,51,Colorectal Cancer,Colon Adenocarcinoma,91,COAD,46.22,0:LIVING,1,Metastatic,Matched,3.066666667,Colon,Female,COLO,Respiratory System,Lung,17,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
33988,50,Bone Cancer,Osteosarcoma,74,OS,9.79,1:DECEASED,1,Metastatic,Matched,2.533333333,NA,Male,SARC,Stomach,Epigastric mass,37,"Tremelimumab, Durvalumab",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1/CTLA4,40,0.009552724,0.132759678,0,0.019284916,0,0,0
34071,65,Soft Tissue Sarcoma,Leiomyosarcoma,39,LMS,21.48,1:DECEASED,1,Metastatic,Matched,1.3,NA,Male,SARC,Soft Tissue,Supraclavicular Mass,15,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
34115,60,Pancreatic Cancer,Pancreatic Adenocarcinoma,182,PAAD,42.77,1:DECEASED,1,Metastatic,Matched,6.133333333,Pancreas,Female,PANC,Liver,Liver,35,NA,NA,NA,NA,No,NA,48,NA,NA,NA,NA,NA,NA,NA
34117,35,"Skin Cancer, Non-Melanoma",Basal Cell Carcinoma,109,BCC,30.68,1:DECEASED,1,Metastatic,Matched,3.7,Skin,Male,BCC,Chest Wall,Chest wall,41,NA,NA,NA,NA,No,NA,51,NA,NA,NA,NA,NA,NA,NA
34118,51,Breast Cancer,Breast Invasive Ductal Carcinoma,76,IDC,25.43,0:LIVING,1,Local Recurrence,Matched,2.566666667,Breast,Female,BRCA,Breast,Breast,50,NA,NA,NA,NA,No,NA,48,NA,NA,NA,NA,NA,NA,NA
34120,54,Breast Cancer,Breast Invasive Ductal Carcinoma,276,IDC,35.97,1:DECEASED,1,Metastatic,Matched,9.133333333,Breast,Female,BRCA,Liver,Liver,33,NA,NA,NA,NA,No,NA,79,NA,NA,NA,NA,NA,NA,NA
34121,57,Breast Cancer,Breast Invasive Ductal Carcinoma,105,IDC,14.19,1:DECEASED,1,Metastatic,Matched,3.533333333,Breast,Female,BRCA,Chest Wall,Pleura,21,BMS-986205 (P1T986205)/IDO1 inhibitor + nivolumab,Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1/IDO-1,33,0.003276524,0.060384268,0,0.00151707,0.03657823,0,0
34122,55,Colorectal Cancer,Colon Adenocarcinoma,42,COAD,35.87,0:LIVING,1,Metastatic,Matched,1.433333333,Colon,Male,COLO,Liver,Liver,24,NA,NA,NA,NA,No,NA,50,NA,NA,NA,NA,NA,NA,NA
34159,47,Renal Cell Carcinoma,Renal Cell Carcinoma,36,RCC,27.2,0:LIVING,1,Metastatic,Matched,1.2,Kidney,Male,KDNY,Liver,Liver,28,Nivolumab,Physician assessed PR,Durable clinical benefit,Mut per Mb < 10,Yes,PD-1,47,0,0.221102023,0,0.095126651,0.067216402,0,0.084402519
34161,65,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,93,LUAD,7.72,1:DECEASED,1,Metastatic,Matched,3.2,Lung,Female,LUNG,Lymphatic System,Lymph Node,0,NA,NA,NA,NA,No,NA,32,NA,NA,NA,NA,NA,NA,NA
34162,58,Glioma,Ependymoma,42,EPM,165.41,0:LIVING,1,Local Recurrence,Matched,1.433333333,NA,Male,CNS-PNS,Spine,Spine,2,NA,NA,NA,NA,No,NA,95,NA,NA,NA,NA,NA,NA,NA
34211,39,Endometrial Cancer,Uterine Endometrioid Carcinoma,86,UEC,8.77,1:DECEASED,1,Metastatic,Matched,2.866666667,Uterus,Female,UCEC,Soft Tissue,Pelvic Mass,9,"Nivolumab (P1T986205),BMS-986205 (P1T986205)/IDO1 inhibitor",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1/IDO-1,63,0,0.125683642,0,0.034319988,0.047231943,0,0.034407323
34215,67,Ovarian Cancer,High-Grade Serous Ovarian Cancer,66,HGSOC,30.81,0:LIVING,1,Local Recurrence,Matched,2.166666667,Ovary,Female,OV,Intestine,Colon,1,NA,NA,NA,NA,No,NA,24,NA,NA,NA,NA,NA,NA,NA
34252,45,Soft Tissue Sarcoma,Leiomyosarcoma,40,LMS,33.05,0:LIVING,1,Local Recurrence,Matched,1.366666667,NA,Male,SARC,Soft Tissue,Leg,53,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
34288,67,Pancreatic Cancer,Pancreatic Adenocarcinoma,49,PAAD,8.84,1:DECEASED,1,Metastatic,Matched,1.633333333,Pancreas,Male,PANC,Liver,Liver,3,NA,NA,NA,NA,No,NA,34,NA,NA,NA,NA,NA,NA,NA
34332,24,Soft Tissue Sarcoma,Alveolar Soft Part Sarcoma,9,ASPS,19.12,1:DECEASED,1,Metastatic,Matched,0.3,NA,Male,SARC,Lymphatic System,Lymph Node,0,NA,NA,NA,NA,No,NA,53,NA,NA,NA,NA,NA,NA,NA
34491,56,Pancreatic Cancer,Pancreatic Adenocarcinoma,50,PAAD,22.54,0:LIVING,1,Metastatic,Matched,1.633333333,Pancreas,Female,PANC,Liver,Liver,11,NA,NA,NA,NA,No,NA,59,NA,NA,NA,NA,NA,NA,NA
34708,82,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,443,LUSC,7.92,1:DECEASED,1,Local Recurrence,Matched,15.1,Lung,Female,LUNG,Respiratory System,Lung,47,NA,NA,NA,NA,No,NA,54,NA,NA,NA,NA,NA,NA,NA
35234,67,Breast Cancer,Breast Invasive Lobular Carcinoma,109,ILC,84.33,0:LIVING,1,Metastatic,Matched,3.6,Breast,Female,BRCA,Lymphatic System,Lymph Node,15,NA,NA,NA,NA,No,NA,32,NA,NA,NA,NA,NA,NA,NA
35258,63,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,101,LUAD,14.82,1:DECEASED,1,Local Recurrence,Matched,3.4,Lung,Male,LUNG,Respiratory System,Lung,14,Nivolumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,42,0,0.101877045,0,0.047735743,0.062387151,0,0.001341642
35260,77,Soft Tissue Sarcoma,Fibrosarcoma,41,FIBS,45.07,1:DECEASED,1,Metastatic,Matched,1.366666667,NA,Male,SARC,Soft Tissue,Groin,11,NA,NA,NA,NA,No,NA,77,NA,NA,NA,NA,NA,NA,NA
35289,48,Colorectal Cancer,Colon Adenocarcinoma,74,COAD,8.25,1:DECEASED,1,Metastatic,Matched,2.5,Colon,Male,COLO,Liver,Liver,0,NA,NA,NA,NA,No,NA,29,NA,NA,NA,NA,NA,NA,NA
35290,86,Melanoma,Uveal Melanoma,17,UM,10.74,1:DECEASED,1,Metastatic,Matched,0.5666666667,Eye,Male,UVM,Liver,Liver,14,Pembrolizumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,74,0,0.125540969,0,0.057046253,0.01274642,0,0.03529177
35336,51,Hepatobiliary Cancer,Cholangiocarcinoma,105,CHOL,15.87,1:DECEASED,1,Metastatic,Matched,3.533333333,Bile Duct,Male,CHOL,Liver,Liver,27,NA,NA,NA,NA,No,NA,85,NA,NA,NA,NA,NA,NA,NA
35337,64,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,55,LUAD,19.84,1:DECEASED,1,Local Recurrence,Matched,1.866666667,Lung,Male,LUNG,Respiratory System,Lung,0,Nivolumab,Physician assessed SD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,43,0,0.176080389,0,0.050040969,0.05218824,0,0.073450942
36037,63,Breast Cancer,Breast Invasive Ductal Carcinoma,44,IDC,23.46,0:LIVING,1,Local Recurrence,Matched,1.5,Breast,Female,BRCA,Breast,Breast,25,NA,NA,NA,NA,No,NA,84,NA,NA,NA,NA,NA,NA,NA
36062,56,Esophagogastric Cancer,Stomach Adenocarcinoma,200,STAD,13.27,1:DECEASED,1,Metastatic,Matched,6.833333333,Stomach,Female,STAD,Liver,Liver,30,NA,NA,NA,NA,No,NA,63,NA,NA,NA,NA,NA,NA,NA
36063,58,Melanoma,Melanoma,199,MEL,18.96,1:DECEASED,1,Local Recurrence,Matched,6.666666667,Skin,Male,SKCM,Lymphatic System,Lymph Node,26,"Nivolumab (P1T986205),BMS-986205 (P1T986205)",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1/IDO-1,84,0.003148181,0.0062115,0,0.040115713,0.017969092,0,0.014374284
36065,37,Breast Cancer,Breast Invasive Ductal Carcinoma,112,IDC,21.91,0:LIVING,1,Metastatic,Matched,3.7,Breast,Female,BRCA,Soft Tissue,Hip,39,NA,NA,NA,NA,No,NA,34,NA,NA,NA,NA,NA,NA,NA
36067,56,Head and Neck Cancer,Oropharynx Squamous Cell Carcinoma,199,OPHSC,7.23,1:DECEASED,1,Local Recurrence,Matched,6.733333333,NA,Male,HNSC,Head & Neck,Tongue,24,"Tremelimumab, Durvalumab",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1/CTLA4,63,0.024661406,0.190547979,0,0.09057991,0.032740574,0,0
36068,69,Salivary Gland Cancer,Salivary Carcinoma,41,SACA,17.77,1:DECEASED,1,Unknown,Matched,1.433333333,Unknown,Male,SECR,Head & Neck,Submandibular Gland,0,NA,NA,NA,NA,No,NA,37,NA,NA,NA,NA,NA,NA,NA
36069,70,Ampullary Cancer,Pancreatobiliary Ampullary Carcinoma,227,PAMPCA,5.39,1:DECEASED,1,Metastatic,Matched,7.566666667,Bile Duct,Female,CHOL,Liver,Liver,52,Nivolumab,Not evaluable,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,48,0,0.164458366,0,0.097251801,0.028092743,0,0.100459518
36509,69,Bone Cancer,Fibroblastic Osteosarcoma,50,FIOS,12.29,1:DECEASED,1,Metastatic,Matched,1.7,NA,Male,SARC,Chest Wall,Chest wall,39,NA,NA,NA,NA,No,NA,93,NA,NA,NA,NA,NA,NA,NA
36621,50,Breast Cancer,Breast Invasive Ductal Carcinoma,48,IDC,21.32,1:DECEASED,1,Metastatic,Matched,1.633333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,22,NA,NA,NA,NA,No,NA,59,NA,NA,NA,NA,NA,NA,NA
36622,31,Embryonal Tumor,Primitive Neuroectodermal Tumor,51,PNET,13.53,1:DECEASED,1,Metastatic,Matched,1.733333333,NA,Male,CNS-PNS,Soft Tissue,Calf,36,NA,NA,NA,NA,No,NA,100,NA,NA,NA,NA,NA,NA,NA
36684,62,Ovarian Cancer,Clear Cell Ovarian Cancer,137,CCOV,14.59,1:DECEASED,1,Metastatic,Matched,4.6,Ovary,Female,OV,Reproductive System,Omental Mass,21,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
36686,63,Soft Tissue Sarcoma,Leiomyosarcoma,38,LMS,46.65,0:LIVING,1,Metastatic,Matched,1.266666667,NA,Female,SARC,Lymphatic System,Lymph Node,18,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
36700,36,Breast Cancer,Breast Invasive Ductal Carcinoma,111,IDC,6.04,1:DECEASED,1,Metastatic,Matched,3.766666667,Breast,Female,BRCA,Liver,Liver,46,NA,NA,NA,NA,No,NA,92,NA,NA,NA,NA,NA,NA,NA
36701,42,Pancreatic Cancer,Pancreatic Adenocarcinoma,44,PAAD,20.63,0:LIVING,1,Metastatic,Matched,1.533333333,Pancreas,Female,PANC,Liver,Liver,34,NA,NA,NA,NA,No,NA,44,NA,NA,NA,NA,NA,NA,NA
36717,33,Pancreatic Cancer,Pancreatic Neuroendocrine Tumor,353,PANET,37.75,0:LIVING,1,Metastatic,Matched,11.86666667,Pancreas,Female,PANC,Soft Tissue,Pelvic Mass,3,NA,NA,NA,NA,No,NA,68,NA,NA,NA,NA,NA,NA,NA
36718,73,Colorectal Cancer,Colon Adenocarcinoma,135,COAD,49.57,0:LIVING,1,Metastatic,Matched,4.666666667,Colon,Male,COLO,Respiratory System,Lung,15,NA,NA,NA,NA,No,NA,62,NA,NA,NA,NA,NA,NA,NA
36748,56,Pancreatic Cancer,Pancreatic Adenocarcinoma,40,PAAD,21.85,0:LIVING,1,Metastatic,Matched,1.333333333,Pancreas,Female,PANC,Liver,Liver,15,NA,NA,NA,NA,No,NA,54,NA,NA,NA,NA,NA,NA,NA
36749,67,Melanoma,Uveal Melanoma,30,UM,43.63,0:LIVING,1,Metastatic,Matched,1,Eye,Female,UVM,Liver,Liver,16,NA,NA,NA,NA,No,NA,88,NA,NA,NA,NA,NA,NA,NA
36750,58,Esophagogastric Cancer,Esophageal Adenocarcinoma,93,ESCA,8.61,1:DECEASED,1,Metastatic,Matched,3.1,Esophagus,Male,ESCA,Liver,Liver,21,NA,NA,NA,NA,No,NA,83,NA,NA,NA,NA,NA,NA,NA
36962,29,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,48,LUAD,8.94,1:DECEASED,1,Local Recurrence,Matched,1.666666667,Lung,Female,LUNG,Chest Wall,Pleura,48,"Tremelimumab, Durvalumab",Stable disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1/CTLA-4,72,0,0.174223664,0,0.033347715,0.032358255,0,0
36963,43,Soft Tissue Sarcoma,Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma,38,MFH,22.96,0:LIVING,1,Local Recurrence,Matched,1.266666667,NA,Female,SARC,Soft Tissue,Groin,2,NA,NA,NA,NA,No,NA,99,NA,NA,NA,NA,NA,NA,NA
37013,52,Breast Cancer,Breast Invasive Ductal Carcinoma,144,IDC,35.74,1:DECEASED,1,Local Recurrence,Matched,4.933333333,Breast,Female,BRCA,Breast,Breast,44,NA,NA,NA,NA,No,NA,66,NA,NA,NA,NA,NA,NA,NA
37025,55,Pancreatic Cancer,Pancreatic Adenocarcinoma,25,PAAD,22.31,0:LIVING,1,Metastatic,Matched,0.8333333333,Pancreas,Male,PANC,Liver,Liver,0,NA,NA,NA,NA,No,NA,21,NA,NA,NA,NA,NA,NA,NA
37026,67,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,128,LUAD,43,0:LIVING,1,Local Recurrence,Matched,4.366666667,Lung,Female,LUNG,Lymphatic System,Lymph Node,15,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
37027,45,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,40,LUAD,16.39,1:DECEASED,1,Local Recurrence,Matched,1.333333333,Lung,Female,LUNG,Lymphatic System,Lymph Node,25,Nivolumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,30,0.043611637,0.019601522,0,0,0.038446419,0.002377686,0
37076,51,Breast Cancer,Breast Invasive Ductal Carcinoma,208,IDC,40.08,1:DECEASED,1,Metastatic,Matched,7,Breast,Female,BRCA,Chest Wall,Chest wall,24,NA,NA,NA,NA,No,NA,47,NA,NA,NA,NA,NA,NA,NA
37077,65,Breast Cancer,Breast Invasive Ductal Carcinoma,35,IDC,49.18,1:DECEASED,1,Metastatic,Matched,1.166666667,Breast,Female,BRCA,Liver,Liver,21,NA,NA,NA,NA,No,NA,68,NA,NA,NA,NA,NA,NA,NA
37078,42,Breast Cancer,Breast Invasive Ductal Carcinoma,17,IDC,22.8,0:LIVING,1,Metastatic,Matched,0.6333333333,Breast,Female,BRCA,Abdomen,Abdominal Mass,6,NA,NA,NA,NA,No,NA,66,NA,NA,NA,NA,NA,NA,NA
37080,70,Colorectal Cancer,Colon Adenocarcinoma,72,COAD,28.12,1:DECEASED,1,Metastatic,Matched,2.4,Colon,Male,COLO,Liver,Liver,41,"Tremelimumab, Durvalumab",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1/CTLA-4,69,0,0.18788261,0,0.080392961,0.030207291,0,0.034081854
37093,27,Renal Cell Carcinoma,Papillary Renal Cell Carcinoma,27,PRCC,13.04,1:DECEASED,1,Unknown,Matched,0.9,Kidney,Male,KDNY,Soft Tissue,Pelvic Mass,22,Nivolumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,55,0.003608033,0.069985451,0,0,0.037181146,0,0.004109199
37095,31,Thymic Tumor,Thymic Carcinoma,20,THYC,32.49,0:LIVING,1,Metastatic,Matched,0.6666666667,Thymus,Female,THYM,Respiratory System,Lung,0,NA,NA,NA,NA,No,NA,85,NA,NA,NA,NA,NA,NA,NA
37097,40,Breast Cancer,Breast Invasive Ductal Carcinoma,48,IDC,31.67,0:LIVING,1,Metastatic,Matched,1.633333333,Breast,Female,BRCA,Liver,Liver,23,NA,NA,NA,NA,No,NA,80,NA,NA,NA,NA,NA,NA,NA
37145,43,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,94,LUAD,35.22,0:LIVING,1,Local Recurrence,Matched,3.133333333,Lung,Female,LUNG,Lymphatic System,Lymph Node,0,NA,NA,NA,NA,No,NA,25,NA,NA,NA,NA,NA,NA,NA
37146,38,Breast Cancer,Breast Invasive Ductal Carcinoma,162,IDC,18.13,1:DECEASED,1,Metastatic,Matched,5.4,Breast,Female,BRCA,Lymphatic System,Lymph Node,67,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
37155,59,Colorectal Cancer,Colon Adenocarcinoma,68,COAD,20.2,0:LIVING,1,Metastatic,Matched,2.266666667,Colon,Female,COLO,Liver,Liver,24,NA,NA,NA,NA,No,NA,61,NA,NA,NA,NA,NA,NA,NA
37249,54,Pancreatic Cancer,Pancreatic Adenocarcinoma,44,PAAD,12.88,1:DECEASED,1,Metastatic,Matched,1.5,Pancreas,Male,PANC,Liver,Liver,26,NA,NA,NA,NA,No,NA,86,NA,NA,NA,NA,NA,NA,NA
37297,55,Esophagogastric Cancer,Adenocarcinoma of the Gastroesophageal Junction,120,GEJ,11.3,1:DECEASED,1,Metastatic,Matched,4.166666667,Gastroesophageal Junction,Male,ESCA,Liver,Liver,47,NA,NA,NA,NA,No,NA,58,NA,NA,NA,NA,NA,NA,NA
37311,54,Colorectal Cancer,Colon Adenocarcinoma,199,COAD,79.8,1:DECEASED,1,Metastatic,Matched,6.766666667,Colon,Female,COLO,Liver,Liver,43,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
37312,72,Breast Cancer,Breast Invasive Ductal Carcinoma,70,IDC,13.24,1:DECEASED,1,Metastatic,Matched,2.366666667,Breast,Female,BRCA,Lymphatic System,Lymph Node,28,NA,NA,NA,NA,No,NA,55,NA,NA,NA,NA,NA,NA,NA
37365,54,Breast Cancer,Breast Invasive Ductal Carcinoma,30,IDC,17.31,1:DECEASED,1,Metastatic,Matched,0.9666666667,Breast,Female,BRCA,Liver,Liver,15,NA,NA,NA,NA,No,NA,43,NA,NA,NA,NA,NA,NA,NA
37619,63,Breast Cancer,Breast Invasive Ductal Carcinoma,99,IDC,16.16,1:DECEASED,1,Local Recurrence,Matched,3.3,Breast,Female,BRCA,Breast,Breast,56,NA,NA,NA,NA,No,NA,69,NA,NA,NA,NA,NA,NA,NA
37620,50,Breast Cancer,Breast Invasive Ductal Carcinoma,456,IDC,19.61,0:LIVING,1,Metastatic,Matched,15.43333333,Breast,Female,BRCA,Chest Wall,Sternum,13,NA,NA,NA,NA,No,NA,95,NA,NA,NA,NA,NA,NA,NA
37643,44,Breast Sarcoma,Breast Angiosarcoma,23,BA,18.2,0:LIVING,1,Metastatic,Matched,0.7666666667,Breast,Female,SARC,Reproductive System,Ovary,0,NA,NA,NA,NA,No,NA,41,NA,NA,NA,NA,NA,NA,NA
37716,36,Colorectal Cancer,Colon Adenocarcinoma,135,COAD,24.28,1:DECEASED,1,Metastatic,Matched,4.666666667,Colon,Female,COLO,Abdomen,Abdominal Mass,2,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
37717,67,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,39,LUAD,23.03,1:DECEASED,1,Metastatic,Matched,1.3,Lung,Female,LUNG,Chest Wall,Chest wall,29,Nivolumab,Not evaluable,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,45,0.007299381,0.08499503,0,0.001187295,0.000857164,0,0
37718,61,Pancreatic Cancer,Pancreatic Adenocarcinoma,51,PAAD,19.55,1:DECEASED,1,Metastatic,Matched,1.733333333,Pancreas,Male,PANC,Liver,Liver,21,NA,NA,NA,NA,No,NA,66,NA,NA,NA,NA,NA,NA,NA
37719,52,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,91,LUAD,10.78,1:DECEASED,1,Unknown,Matched,3.133333333,Lung,Female,LUNG,Chest Wall,Pleura,21,Nivolumab,Physician assessed PD,No durable clinical benefit,Mut per Mb < 10,Yes,PD-1,33,0.006310248,0.169524808,0,0.074168441,0,0,0.044051799
37720,71,Colorectal Cancer,Colon Adenocarcinoma,133,COAD,31.31,1:DECEASED,1,Metastatic,Matched,4.5,Colon,Male,COLO,Liver,Liver,0,NA,NA,NA,NA,No,NA,60,NA,NA,NA,NA,NA,NA,NA
37828,59,Hepatobiliary Cancer,Cholangiocarcinoma,59,CHOL,10.78,1:DECEASED,1,Metastatic,Matched,2,Bile Duct,Male,CHOL,Liver,Liver,22,NA,NA,NA,NA,No,NA,24,NA,NA,NA,NA,NA,NA,NA
37840,42,Mature T and NK Neoplasms,"Peripheral T-Cell lymphoma, NOS",9,PTCL,22.57,0:LIVING,1,Metastatic,Matched,0.3,NA,Male,LYMP,Lymphatic System,Lymph Node,1,NA,NA,NA,NA,No,NA,53,NA,NA,NA,NA,NA,NA,NA
37842,69,Ovarian Cancer,Low-Grade Serous Ovarian Cancer,27,LGSOC,68.53,0:LIVING,1,Metastatic,Matched,0.8666666667,Ovary,Female,OV,Spine,Spleen,15,NA,NA,NA,NA,No,NA,100,NA,NA,NA,NA,NA,NA,NA
37844,70,Breast Cancer,Breast Invasive Ductal Carcinoma,37,IDC,121.58,1:DECEASED,1,Metastatic,Matched,1.233333333,Breast,Female,BRCA,Liver,Liver,11,NA,NA,NA,NA,No,NA,79,NA,NA,NA,NA,NA,NA,NA
37845,68,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,47,LUAD,4.47,0:LIVING,1,Metastatic,Matched,1.6,Lung,Female,LUNG,Respiratory System,Lung,0,NA,NA,NA,NA,No,NA,53,NA,NA,NA,NA,NA,NA,NA
37862,55,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,40,LUAD,18.63,0:LIVING,1,Local Recurrence,Matched,1.333333333,Lung,Male,LUNG,Lymphatic System,Lymph Node,21,NA,NA,NA,NA,No,NA,27,NA,NA,NA,NA,NA,NA,NA
37916,54,Breast Cancer,Breast Invasive Ductal Carcinoma,200,IDC,20.73,0:LIVING,1,Metastatic,Matched,6.633333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,3,NA,NA,NA,NA,No,NA,38,NA,NA,NA,NA,NA,NA,NA
37917,64,Ovarian Cancer,High-Grade Serous Ovarian Cancer,152,HGSOC,96.35,0:LIVING,1,Metastatic,Matched,5.166666667,Ovary,Female,OV,Abdomen,Rectroperitoneum,54,NA,NA,NA,NA,No,NA,66,NA,NA,NA,NA,NA,NA,NA
37918,38,Breast Cancer,Breast Invasive Ductal Carcinoma,42,IDC,9.76,1:DECEASED,1,Metastatic,Matched,1.4,Breast,Female,BRCA,Lymphatic System,Lymph Node,4,NA,NA,NA,NA,No,NA,25,NA,NA,NA,NA,NA,NA,NA
37919,58,Breast Cancer,Breast Invasive Ductal Carcinoma,42,IDC,20.43,0:LIVING,1,Metastatic,Matched,1.4,Breast,Female,BRCA,Lymphatic System,Lymph Node,22,NA,NA,NA,NA,No,NA,21,NA,NA,NA,NA,NA,NA,NA
37967,66,Pancreatic Cancer,Pancreatic Adenocarcinoma,49,PAAD,16.82,1:DECEASED,1,Metastatic,Matched,1.633333333,Pancreas,Female,PANC,Liver,Liver,0,NA,NA,NA,NA,No,NA,33,NA,NA,NA,NA,NA,NA,NA
37970,59,Hepatobiliary Cancer,Cholangiocarcinoma,42,CHOL,12.32,1:DECEASED,1,Metastatic,Matched,1.433333333,Bile Duct,Male,CHOL,Liver,Liver,25,"Tremelimumab, Durvalumab",Progressive disease,No durable clinical benefit,Mut per Mb < 10,Yes,PD-L1/CTLA-4,46,0.016210194,0.205107082,0,0.144700934,0.042589254,0,0.031662814
38013,28,Esophagogastric Cancer,Adenocarcinoma of the Gastroesophageal Junction,1730,GEJ,27.2,1:DECEASED,1,Metastatic,Matched,58.63333333,Gastroesophageal Junction,Female,ESCA,Adrenal Gland,Adrenal,7,NA,NA,NA,NA,No,NA,43,NA,NA,NA,NA,NA,NA,NA
38060,56,Breast Cancer,Breast Invasive Ductal Carcinoma,47,IDC,23.19,0:LIVING,1,Metastatic,Matched,1.6,Breast,Female,BRCA,Lymphatic System,Lymph Node,16,NA,NA,NA,NA,No,NA,65,NA,NA,NA,NA,NA,NA,NA
38063,43,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,56,LUAD,20.14,0:LIVING,1,Local Recurrence,Matched,1.866666667,Lung,Female,LUNG,Lymphatic System,Lymph Node,25,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
38077,79,Mature B-Cell Neoplasms,"Diffuse Large B-Cell Lymphoma, NOS",98,DLBCLNOS,24.84,0:LIVING,1,Local Recurrence,Matched,3.3,NA,Male,LYMP,Intestine,Colon,2,NA,NA,NA,NA,No,NA,98,NA,NA,NA,NA,NA,NA,NA
38119,45,Ovarian Cancer,High-Grade Serous Ovarian Cancer,216,HGSOC,61.7,1:DECEASED,1,Metastatic,Matched,7.233333333,Ovary,Female,OV,Reproductive System,Omentum,57,NA,NA,NA,NA,No,NA,34,NA,NA,NA,NA,NA,NA,NA
38120,66,Colorectal Cancer,Colon Adenocarcinoma,114,COAD,31.34,0:LIVING,1,Metastatic,Matched,3.9,Colon,Female,COLO,Lymphatic System,Lymph Node,5,NA,NA,NA,NA,No,NA,46,NA,NA,NA,NA,NA,NA,NA
38228,42,Soft Tissue Sarcoma,Leiomyosarcoma,56,LMS,28.42,0:LIVING,1,Metastatic,Matched,1.966666667,NA,Female,SARC,Liver,Liver,16,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
38231,64,Mature B-Cell Neoplasms,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,40,CLLSLL,15.64,1:DECEASED,1,Unknown,Matched,1.333333333,Blood,Male,LYMP,Abdomen,Peritoneal Fluid,24,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
38250,41,Breast Cancer,Breast Invasive Ductal Carcinoma,24,IDC,7.98,0:LIVING,1,Metastatic,Matched,0.8333333333,Breast,Female,BRCA,Liver,Liver,15,NA,NA,NA,NA,No,NA,52,NA,NA,NA,NA,NA,NA,NA
38261,32,Breast Cancer,Breast Invasive Ductal Carcinoma,20,IDC,20.53,0:LIVING,1,Local Recurrence,Matched,0.6666666667,Breast,Female,BRCA,Breast,Breast,19,NA,NA,NA,NA,No,NA,38,NA,NA,NA,NA,NA,NA,NA
38357,46,Breast Cancer,Breast Invasive Ductal Carcinoma,27,IDC,18.63,0:LIVING,1,Metastatic,Matched,0.9333333333,Breast,Female,BRCA,Lymphatic System,Lymph Node,2,NA,NA,NA,NA,No,NA,33,NA,NA,NA,NA,NA,NA,NA
38453,54,Ovarian Cancer,High-Grade Serous Ovarian Cancer,106,HGSOC,41.85,0:LIVING,1,Metastatic,Matched,3.566666667,Ovary,Female,OV,Reproductive System,Vaginal Vault,55,NA,NA,NA,NA,No,NA,85,NA,NA,NA,NA,NA,NA,NA
38501,45,Breast Cancer,Breast Invasive Ductal Carcinoma,102,IDC,26.25,1:DECEASED,1,Metastatic,Matched,3.433333333,Breast,Female,BRCA,Brain,Brain,53,NA,NA,NA,NA,No,NA,54,NA,NA,NA,NA,NA,NA,NA
38505,58,Pancreatic Cancer,Pancreatic Adenocarcinoma,41,PAAD,20.3,0:LIVING,1,Metastatic,Matched,1.366666667,Pancreas,Male,PANC,Liver,Liver,0,NA,NA,NA,NA,No,NA,21,NA,NA,NA,NA,NA,NA,NA
38506,70,Colorectal Cancer,Colon Adenocarcinoma,83,COAD,26.05,1:DECEASED,1,Metastatic,Matched,2.766666667,Colon,Male,COLO,Liver,Liver,29,NA,NA,NA,NA,No,NA,89,NA,NA,NA,NA,NA,NA,NA
38507,44,Breast Cancer,Breast Invasive Ductal Carcinoma,122,IDC,19.35,0:LIVING,1,Local Recurrence,Matched,4.1,Breast,Female,BRCA,Lymphatic System,Lymph Node,36,NA,NA,NA,NA,No,NA,29,NA,NA,NA,NA,NA,NA,NA
38536,62,Pancreatic Cancer,Pancreatic Adenocarcinoma,81,PAAD,9.59,1:DECEASED,1,Metastatic,Matched,2.7,Pancreas,Male,PANC,Liver,Liver,40,NA,NA,NA,NA,No,NA,57,NA,NA,NA,NA,NA,NA,NA
38537,49,Pancreatic Cancer,Pancreatic Adenocarcinoma,38,PAAD,12.55,1:DECEASED,1,Metastatic,Matched,1.266666667,Pancreas,Male,PANC,Liver,Liver,20,NA,NA,NA,NA,No,NA,53,NA,NA,NA,NA,NA,NA,NA
38569,39,Breast Cancer,Breast Invasive Ductal Carcinoma,132,IDC,18.69,0:LIVING,1,Metastatic,Matched,4.5,Breast,Female,BRCA,Chest Wall,Sternal mass,8,NA,NA,NA,NA,No,NA,31,NA,NA,NA,NA,NA,NA,NA
38574,61,Breast Cancer,Breast Invasive Ductal Carcinoma,23,IDC,33.02,0:LIVING,1,Local Recurrence,Matched,0.7666666667,Breast,Female,BRCA,Breast,Breast,18,NA,NA,NA,NA,No,NA,76,NA,NA,NA,NA,NA,NA,NA
38575,66,Soft Tissue Sarcoma,Leiomyosarcoma,31,LMS,33.48,1:DECEASED,1,Metastatic,Matched,1.133333333,NA,Female,SARC,Respiratory System,Lung,46,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
38599,75,Melanoma,Melanoma,1504,MEL,19.94,0:LIVING,1,Metastatic,Matched,51,Skin,Male,SKCM,Respiratory System,Lung,3,"Nivolumab (P1T986205),BMS-986205 (P1T986205)/IDO1 inhibitor",Physician assessed PD,No durable clinical benefit,Mut per Mb >= 10,Yes,PD-1/IDO-1,42,0,0.470758683,0,0.813721291,0.140538772,0,0.011228847
38601,50,Colorectal Cancer,Colon Adenocarcinoma,77,COAD,35.45,1:DECEASED,1,Metastatic,Matched,2.6,Colon,Male,COLO,Respiratory System,Lung,25,NA,NA,NA,NA,No,NA,47,NA,NA,NA,NA,NA,NA,NA
38673,64,Soft Tissue Sarcoma,Dedifferentiated Liposarcoma,24,DDLS,52.76,0:LIVING,1,Metastatic,Matched,0.8,NA,Male,SARC,Soft Tissue,Psoas Muscle,4,NA,NA,NA,NA,No,NA,57,NA,NA,NA,NA,NA,NA,NA
38674,56,CNS Cancer,Meningioma,23,MNG,34.23,0:LIVING,1,Local Recurrence,Matched,0.8,NA,Female,CNS-PNS,Brain,Brain,12,NA,NA,NA,NA,No,NA,56,NA,NA,NA,NA,NA,NA,NA
38675,67,Colorectal Cancer,Colon Adenocarcinoma,81,COAD,17.28,1:DECEASED,1,Metastatic,Matched,2.833333333,Colon,Male,COLO,Lymphatic System,Lymph Node,40,NA,NA,NA,NA,No,NA,42,NA,NA,NA,NA,NA,NA,NA
38705,55,Breast Cancer,Adenoid Cystic Breast Cancer,14,ACBC,76.74,0:LIVING,1,Metastatic,Matched,0.5,Breast,Female,SECR,Liver,Liver,4,NA,NA,NA,NA,No,NA,87,NA,NA,NA,NA,NA,NA,NA
38706,72,Soft Tissue Sarcoma,Leiomyosarcoma,68,LMS,34.07,1:DECEASED,1,Metastatic,Matched,2.3,NA,Female,SARC,Liver,Liver,37,NA,NA,NA,NA,No,NA,90,NA,NA,NA,NA,NA,NA,NA
38725,33,Breast Cancer,Breast Invasive Ductal Carcinoma,141,IDC,17.28,0:LIVING,1,Metastatic,Matched,4.8,Breast,Female,BRCA,Respiratory System,Lung,56,NA,NA,NA,NA,No,NA,70,NA,NA,NA,NA,NA,NA,NA
38726,62,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,74,LUAD,0,0:LIVING,1,Local Recurrence,Matched,2.666666667,Lung,Male,LUNG,Respiratory System,Lung,0,NA,NA,NA,NA,No,NA,28,NA,NA,NA,NA,NA,NA,NA
38727,75,Non-Small Cell Lung Cancer,Lung Neuroendocrine Tumor,21,LNET,28.81,0:LIVING,1,Metastatic,Matched,0.7,Lung,Male,LUNG,Liver,Liver,5,NA,NA,NA,NA,No,NA,88,NA,NA,NA,NA,NA,NA,NA
38744,70,Melanoma,Uveal Melanoma,16,UM,31.18,0:LIVING,1,Metastatic,Matched,0.5333333333,Eye,Male,UVM,Liver,Liver,3,NA,NA,NA,NA,No,NA,72,NA,NA,NA,NA,NA,NA,NA
38759,69,Pancreatic Cancer,Pancreatic Adenocarcinoma,42,PAAD,31.93,1:DECEASED,1,Metastatic,Matched,1.4,Pancreas,Female,PANC,Lymphatic System,Lymph Node,19,NA,NA,NA,NA,No,NA,41,NA,NA,NA,NA,NA,NA,NA
38792,61,Breast Cancer,Breast Invasive Ductal Carcinoma,49,IDC,96.35,0:LIVING,1,Local Recurrence,Matched,1.633333333,Breast,Female,BRCA,Breast,Breast,25,NA,NA,NA,NA,No,NA,93,NA,NA,NA,NA,NA,NA,NA
38850,50,Breast Cancer,Breast Invasive Ductal Carcinoma,165,IDC,8.02,1:DECEASED,1,Metastatic,Matched,5.6,Breast,Female,BRCA,Liver,Liver,56,NA,NA,NA,NA,No,NA,79,NA,NA,NA,NA,NA,NA,NA
38887,53,Breast Cancer,Breast Invasive Ductal Carcinoma,50,IDC,48.32,0:LIVING,1,Metastatic,Matched,1.666666667,Breast,Female,BRCA,Liver,Liver,23,NA,NA,NA,NA,No,NA,98,NA,NA,NA,NA,NA,NA,NA
38905,31,Ovarian Cancer,Mixed Ovarian Carcinoma,103,MXOV,5.52,1:DECEASED,1,Metastatic,Matched,3.433333333,Ovary,Female,OV,Lymphatic System,Lymph Node,25,NA,NA,NA,NA,No,NA,69,NA,NA,NA,NA,NA,NA,NA
38947,48,Melanoma,Melanoma,441,MEL,18.07,1:DECEASED,1,Metastatic,Matched,15.03333333,Skin,Female,SKCM,Chest Wall,Chest wall,32,Pembrolizumab,Physician assessed SD,No durable clinical benefit,Mut per Mb >= 10,Yes,PD-1,97,0,0,0,0.009627636,0.016121727,0,0
39044,58,Pancreatic Cancer,Pancreatic Adenocarcinoma,54,PAAD,13.07,1:DECEASED,1,Metastatic,Matched,1.8,Pancreas,Female,PANC,Lymphatic System,Lymph Node,1,NA,NA,NA,NA,No,NA,43,NA,NA,NA,NA,NA,NA,NA
39280,62,Soft Tissue Sarcoma,"Sarcoma, NOS",1889,SARCNOS,26.05,1:DECEASED,1,Local Recurrence,Matched,64.23333333,Lung,Male,MISC,Respiratory System,Lung,43,Pembrolizumab,Physician Assessed SD,Durable clinical benefit,Mut per Mb >= 10,Yes,PD-1,36,0.125128262,0.286176312,0,0.784754031,0.077439508,0,0.041287676